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ABSTRACT 
 
 Since its discovery in 1981, HIV-1 has infected almost 78 million people, and ~39 
million people have died. An effective vaccine for HIV-1 remains an utmost priority. In the 
past several years, tremendous progress has been made in designing different immunogens 
and employing vaccination strategies, with the common goal of eliciting broadly neutralizing 
antibodies (bnAbs) and/or T cell responses against HIV infection. Several bnAbs have been 
isolated from patients, suggesting that the humoral immune system is capable of making such 
antibodies. Unfortunately, none of the immunogens and vaccination strategies has elicited 
bnAbs till date, and thus a tremendous amount of work still lies ahead. Here, we evaluated an 
immune complexing vaccination strategy in rabbits to focus the immune response towards 
critical neutralizing epitopes on HIV-1 by masking the hypervariable, immunodominant V3 
loop on gp120 with a rabbit monoclonal antibody (mAb).  
 Our findings indicate that although the humoral immune response did not increase in 
immune complex vaccinated rabbits as compared to gp120 alone group, we still suppressed 
the V3-specific antibody, as seen by antigen specific antibody titer and fine linear epitope 
mapping. Also, competition of immune complex sera against V3 loop-neutralizing antibodies 
(nAbs) confirm repressed antibody activity towards this epitope. Although, immune complex 
vaccinated rabbits failed to elicit neutralizing antibodies, we have demonstrated the proof of 
concept and feasibility of this approach. Further evaluation of this strategy using alternate 
immunogens like BG505 SOSIP gp140 and eOD-GT8 will be carried out in the near future. 
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CHAPTER I 
 GENERAL INTRODUCTION 
 
Thesis Organization 
This thesis is organized into four chapters. Chapter 1 is a general introduction 
providing literature review on HIV-1, the disease pandemic, envelope glycoprotein based 
immunogens and vaccine development against HIV-1. Chapter 2 is the evaluation of an 
immune complexing strategy for HIV-1 vaccine development. I performed all the 
experiments, analyzed the results and recorded them. Chapter 3 provides general conclusions 
and the future directions. Appendix includes “Characterization of a large panel of rabbit 
monoclonal antibodies against HIV-1 gp120 and isolation of novel neutralizing antibodies 
against the V3 loop”. This is a manuscript published in PLOS ONE journal. I contributed in 
planning, carrying out experiments (fig 1, 2, 5 and 6) and evaluation of results. I also assisted 
in writing the manuscript.  
Introduction 
Human Immunodeficiency Virus  
 Human immunodeficiency virus, abbreviated HIV, is the etiologic agent of acquired 
immunodeficiency syndrome (AIDS), which is a sexually transmitted disease. It belongs to the 
family retroviridae, comprising RNA viruses which can convert their genomic RNA to a DNA 
for during their “life cycle”, and genus Lentivirus, known for their longer incubation periods, as 
the virus can remain in latent phase in the host for years without progressing into actual disease 
[1]. The first case of AIDS was reported in US in 1981[2]. HIV was isolated and recognized as 
causative agent of AIDS in 1983 [3].  
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 HIV has two subtypes: HIV-1 and HIV-2. HIV-1 is the most virulent strain and is 
responsible for the pandemic throughout the world, while HIV-2 is limited to Western and 
Central Africa [4]. HIV-1 is divided into the following groups:  M (Major), O (outlier), and N 
(non-major or outlier) and P.  Group M accounts for most of the HIV-1 infections, which is 
further classified into nine major clades:  A, B, C, D, F, G, H, J and K; as well as circulating 
recombinant forms (like CRF A/B, which is a combination of clade A and B) [5]. 
  HIV-1 infects CD4 positive cells like T helper cells, monocytes, macrophages, dendritic 
cells, etc.; which are important to combating infections [6]. The immune system of the host 
becomes severely compromised due to rapid depletion of CD4 cells, leading to the condition 
termed AIDS.  During this stage, the patients are prone to opportunistic infections such as 
Kaposi’ s sarcoma, lymphoma, tuberculosis, and pneumonia.  
 Almost 78 million people have been infected with HIV, and ~39 million people have 
died since the discovery of HIV in 1981. There were nearly 37 million people living with HIV-1 
globally (2.6 million children) by the end of 2014 with 2 million new infections every year [7] . 
HIV-1 is listed as one of the top 10 leading causes of death [8]. Current anti-retroviral therapies 
can decrease the viral load present in the latent reservoirs but cannot cure or eradicate the virus 
completely. Therefore, many scientists hypothesize that an effective vaccine is the best way to 
control the HIV pandemic. 
 
Structure of HIV-1 
 HIV-1 is an icosahedral shaped retrovirus containing two copies of single stranded 
positive sense RNA molecules as genetic material. The genetic material of the virus encodes 
for structural genes (gag, pol, env); regulatory/accessory genes (tat, rev, nef, vpr, vpu and 
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vpx) and other enzymes required for viral replication (reverse transcriptase, integrase and 
protease). The virus comprises of an outer envelope glycoprotein, which is made up of two 
non-covalently linked subunits, gp120 and gp41, which then associate as trimeric spikes on 
the viral surface as shown in Figure 1. The viral glycoprotein is initially synthesized as a 
gp160 polyprotein, which undergoes cleavage by a cellular protease into gp120 and gp41 [9].  
 The envelope gp120 subunit is comprised of an inner domain, an outer domain and a 
bridging sheet which links the two. It consists of five variable loops (V1-V5), which 
intervenes five conserved regions (C1-C5). Gp41 consists of an external domain, a 
transmembrane domain, and a cytoplasmic tail [10]. The viral envelope surrounds the virus 
core consisting of capsid (p24) and nucleocapsid (p7). The viral matrix (p17) is situated 
between viral core and envelope.  Gp120 initiates the infection by binding to cell surface 
receptors, and gp41 mediates the fusion of viral and host cell membrane [11-13]. 
  
Difficulties in developing an effective vaccine against HIV-1 
 Despite tremendous efforts and progress in the field, an effective vaccine against 
HIV-1 still remains an utmost priority and yet an elusive goal. Science and technology have 
provided in depth knowledge about HIV-1 and the molecular mechanism involved in virus 
entry, but still there is no vaccine available.  
 HIV-1 has evolved various immune evasion strategies to overcome the host immune 
response, which therefore overcomes the effects of drug therapies and vaccines. HIV-1 is 
known for the extensive amount of genetic variation present in multiple subtypes, clades and 
circulating recombinant forms due to the error-prone nature of reverse transcription 
[4,14,15]. HIV-1 strains belonging to same subtypes can differ by 20% in their amino acid 
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sequence, and that can increase up to 35% within a group [14]. This amino acid variability 
also presents a major challenge for virus neutralization because different strains have 
different sensitivities to neutralization based upon sequence differences, with Tier-1 viruses 
the most sensitive and Tier-3 the most resistant [16]. Neutralizing antibodies (nAbs) are 
directed towards conserved epitopes like the CD4 binding site (CD4bs) and the co-receptor 
binding site, which are hidden from the immune system due to conformational masking by 
flanking variable loops [17] and extensive glycosylation [18,19]. Also, gp120 is easily shed 
from the surface, causing elimination of conserved neutralizing antibody epitopes and 
exposure of non-neutralizing epitopes [20]. Different conformations of HIV-1 env can lead to 
poor interactions with low affinity naïve B cell receptors [21]. Finally, the low number of 
trimeric spikes (8-12) on the virion can also limit the avidity and antibody based 
neutralization of the virus [22]. 
 
Broadly neutralizing antibodies 
 Broadly neutralizing antibodies (bnAbs) can neutralize HIV strains belonging to 
different groups thus providing cross clade neutralization. The passive administration of 
bnAbs could provide protection in non-human primate models by decreasing viral load and 
increasing CD4 cell count [23-27]. Therefore, bnAbs have the potential to provide effective 
protection, and eliciting these antibodies remains crucial goal for stopping the viral 
pandemic.  
 However, all the immunogens and vaccine approaches till date have failed to induce 
bnAbs in vaccinated animals and humans. The ability of HIV-1 to evade the host immune 
response presents a major hurdle in field of vaccine development as described above. Most 
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bnAbs demonstrate unusual characteristics like extensive somatic hypermutation from their 
respective germlines and long heavy chain complementarity-determining region 3 (HCDR3) 
[28,29] as these antibodies undergo complex affinity maturation pathways and selection. 
Moreover, exposure of the virus to the host system can provide a different microenvironment 
for evolution and maturation of such bnAbs, which might be difficult to replicate in vaccine 
settings. This suggests that vaccination must guide the antibody maturation pathways 
precisely to elicit such bnAbs.  
 
Broad neutralizing antibodies recognizing different regions on viral envelope 
 Despite all the hurdles and challenges posed by the virus, approximately 20% of 
patients [30,31] develop cross-clade neutralizing antibodies (nAbs) during the chronic phase 
of HIV infection (~2-4 years) [32]. Only rare individuals (~1%) are ‘elite neutralizers’ who 
develop true bnAbs, suggesting that the humoral immune system can successfully prevent 
HIV-1 infection [33]. Many bnAbs have been isolated form HIV-1 infected patients. First-
generation bnAbs were isolated via phage display and Epstein-Barr virus transformation and 
had limited neutralization breadth [34,35]. Recently, new approaches like B-cell capture and 
single cell antibody cloning have isolated next-generation bnAbs, which have more potent 
and broad neutralizing ability [36-38]. 
 These bnAbs recognize four main regions on the viral envelope: CD4bs, epitopes 
associated with N-linked glycans on V1/V2 and N-linked glycans on V3 loop and membrane 
proximal external region (MPER) on gp41 (Figure 2) (as reviewed in [39,40]). Recently, 
epitopes associated with N-linked glycans on gp120/gp41 bridging regions have been 
discovered [41-43]. 
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 Discovery of bnAbs has provided meaningful insight into conserved neutralization 
sites. Molecular modeling, co-crystallization studies and electron microscopy studies have 
provided valuable information regarding bnAb epitopes [29,44]. Understanding how these 
bnAbs recognize their epitopes has been an asset in designing next-generation vaccine 
immunogens. Many groups have tried to engineer env-based immunogens and design 
vaccination strategies with the goal of eliciting bnAbs. To date, no study has elicited such 
bnAbs (as reviewed in [45]). 
 
Peptide based immunogens 
 Early immunogens tested in the HIV-1 field were env derived short peptides based on 
the V3 loop of gp120 [46-49] and MPER in gp41 [50-52]. Unfortunately, vaccination with 
these immunogens resulted in nAbs against Tier-1 viruses only. We now know that epitopes 
recognized by bnAbs are highly conformational, and hence peptide based immunogens might 
never elicit bnAbs. 
 
Epitope scaffolds 
 Epitope scaffold immunogens containing the V3 loop, V3 glycan epitopes, CD4bs 
epitopes (b12) or MPER epitopes (2F5, 4E10) engineered on heterologous protein scaffolds 
were evaluated in the field to elicit conformation-dependent antibodies [53-61]. 
Unfortunately, results from these immunizations were disappointing and failed to mount an 
effective neutralizing response in animals.  
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Gp120 outer-domain (OD) based vaccine immunogens 
 Gp120 comprises of an inner domain (ID), an outer domain (OD) and a bridging 
sheet [12]. The immune response elicited by highly immunodominant ID is mostly non-
neutralizing [62,63]. Therefore, researchers removed the ID to generate OD immunogens. 
The majority of past studies using different versions of OD have been unsuccessful [64-69]. 
Recently, we reported two immunogens, OD and ODx3, designed based on an M group 
consensus sequence (MCON6).  Both immunogens elicited cross-reactive neutralizing 
antibodies against clade B, C, and AE; and even though the neutralizing breadth was 
restricted to Tier-1 viruses, the cross reactivity observed was better than reported by previous 
groups [70]. 
 A new class of engineered outer domain (eOD) immunogens was designed by 
modifying the CD4bs to enhance the binding of CD4bs bnAbs, like VRC01 and 3BNC60, 
and their germline precursors [71]. Further optimization gave rise to eOD-GT6, which when 
multimerized on virus-like nanoparticles could crosslink and activate B cells specific for 
germline VRC01. Immunogenicity studies were carried with an improved version of this 
protein (eOD-GT8) in knock-in mice carrying the heavy chain gene for 3BNC60. Mice sera 
demonstrated strong neutralization only against autologous viruses. Modest neutralization 
was seen against Tier-2 viruses lacking glycosylation at position 276 [72].  
 
Gp120 core immunogens 
 To effectively present the CD4bs and induce CD4bs bnAbs, the gp120 core was 
stabilized by removing the variable loops (V1, V2, V3), and sometimes the amino and 
carboxy termini are also removed [73,74]. Although humoral immune response against 
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CD4bs increased, no efficient Tier-2 nAbs responses were observed [73]. Another 
immunological study with gp120 core proteins lacking major variable loops and masked with 
N-linked glycans also did not induce cross-clade bnAbs [75]. Furthermore, rabbits 
immunized with stabilized gp120 trimer bound to CD4 elicited more potent nAbs than the 
wild type monomer but still failed to induce Tier-2 nAbs [76].  
 
Subunit protein immunogens  
 The virus env is the sole protein exposed on the surface and therefore the only available 
target for vaccine design. The safety of recombinant gp160 was tested in uninfected human 
volunteers. The vaccine was safe and induced T cell responses, but the neutralizing antibodies 
were limited [77-80]. Recombinant gp120 in particular, has been evaluated extensively as an 
immunogen in vaccine studies to determine if they provide protection and induce nAbs [77,81-
87]. Unfortunately, results from Phase I clinical trials demonstrated that monomeric gp120 
elicited nAbs only against laboratory adapted Tier-1 virus strains but not against circulating 
primary virus isolates [86]. Only a few vaccine trials ever advanced to Phase IIb 
(Step/Phambili, HVTN 505) and Phase III (VAX003, VAX004, RV144).  
The Step/Phambili trials evaluated recombinant Adenovirus vector (Ad) expressing 
Gag, Pol and Nef and Env genes. The Step trial, also known as Merck 023/HVTN 502, was 
conducted in America, Australia and Caribbean; and the Phambili trial, also known as HVTN 
503, was conducted in South Africa. Both trials were based on promising results in pre-
clinical studies in non-human primate models (efficacy and cellular immunity) [88]. 
Unfortunately, both trials were unsuccessful in decreasing HIV-infectivity and viral plasma 
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loads in human subjects. The vaccinations for the Phambili trial were halted based on results 
from the Step trial, which demonstrated increased virus infectivity in some subjects [88-90]. 
AIDSVAX B/B (Vax004 trial) evaluated high doses of gp120 from two HIV-1 
subtype B viruses [91,92] and AIDSVAX B/E (Vax003 trial) evaluated recombinant gp120 
from MN and A244 (CRF01-AE) [93]. Unfortunately, these Phase III trials failed to provide 
protection, and neutralization was primarily limited to the Tier-1 MN strain with weak 
neutralization detected against primary isolates. This indicated that nAbs raised in response 
to vaccines might not provide effective protection against a wide range of HIV strains. 
The most recent efficacy trial is HVTN 505, which tested a DNA prime with 
plasmids expressing HIV-1 clade B gag, pol, nef and env protein from multiple clades (A, B 
and C). The booster consisted of recombinant Ad5 vector expressing HIV-1 clade B gag, pol 
and env protein as stated. Unfortunately, the viral plasma loads and infectivity remained 
unaffected, and trial ceased in April 2013 [94]. 
   The only trial to date which decreased the rate of HIV-1 infection, was the RV144 
trial conducted in Thailand. Human subjects were primed with recombinant canarypox vector 
encoding gag, pol, and nef  (ALVAC-HIV [vCP1521]) and membrane anchored gp120, and 
subsequently boosted with gp120-MN and gp120-A244. There was a decrease in HIV-1 
infection by 31% in vaccine recipients, but viral plasma loads and CD4+ T cell count 
remained unaffected [95]. 
 To conclude, subunit protein immunogens were safe and immunogenic but failed to 
demonstrate cross clade neutralization. Also, humoral immune response was higher when 
subunit immunogens were immunized in a heterologous prime boost vaccination regimen 
than alone. One of the major drawbacks of using monomeric gp120 includes shielding of 
10 
conserved epitopes by variable loops (e.g hypervariable immundominant V3 loop) presenting 
decoy epitopes, which ultimately result in the elicitation of strain specific or non nAbs 
[96,97]. As many bnAbs bind to more native functional env rather than gp120, functional env 
might be more relevant to neutralization induction [98]. Therefore, researchers are now 
pursuing immunogens capable of eliciting neutralizing antibody responses against more 
resistant Tier-2 viruses. Although little progress has been made, prior research has provided 
valuable insight into optimization of dose, immunization schedule, choice of adjuvant and 
vector. 
   
Soluble envelope trimers (Non-native trimers) 
 Since recombinant viral vectors expressing subunit proteins did not induce bnAbs, 
researchers required immunogens which better represented the native structure of the virus. 
Also, antibodies elicited in gp120 immunized animals demonstrated very weak binding to the 
trimeric env. It is possible that surfaces exposed on monomeric gp120 might be 
neutralization irrelevant as compared to the native trimer [99,100].  Therefore, trimeric env 
antigens might be a more useful vaccine immunogens [98].  
  Soluble env trimers (gp140) represent a potential solution to this problem. Soluble 
env trimers comprises of gp120 and gp41 ectodomain, which are generated by env truncation 
removing the gp41 cytoplasmic and transmembrane domains. However, truncation of env 
results in instability, causing misfolding and subsequent lack of native conformation [101]. 
The stabilization of soluble trimers has been achieved either by modifying the gp120-gp41 
cleavage site to prevent dissociation resulting in uncleaved trimers (gp140UNC) [142] or by 
fusing the env with trimerization motifs [102-105]. 
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 The immunogenicity studies conducted with soluble env trimers have demonstrated 
better neutralizing antibody responses as compared to gp120, but they were still incapable of 
eliciting bnAbs [106-110]. In human vaccine trials, these soluble trimers failed to generate 
antibody responses against heterologous Tier-2 viruses [111,112]. This might be due to 
misfolding of trimer caused by aberrant disulfide bond formations [113,114]. Also, structural 
rearrangements in trimer can lead to an open conformation exposing the non-nAb epitopes 
[115,116].   
 
Native-like trimers 
 Another approach used by researchers to stabilize the cleaved soluble trimers is the 
introduction of a disulfide bond (SOS) to covalently link gp120 and gp41 ectodomain  [101]. 
To further improve the trimerization, an Ile-to-Pro mutation (I559P) was introduced in gp41 
(together termed ‘SOSIP’) [117]. Immunogenicity studies with these SOSIP trimers from 
subtype clade A induced better responses than gp120, demonstrating weak neutralization 
against autologous Tier-2 viruses in rabbits [118,119]. SOSIP trimers were further improved 
by removing the hydrophobic MPER region by a truncation at position 664 (SOSIP.664) 
[112,120]. Combining clade A Env , BG505 (derived from an infected infant) [121] with 
SOSIP.664 resulted in BG505 SOSIP.664 [122]. BG505 SOSIP.664 trimers are true mimics 
of native viral trimeric spike and have increased solubility and stability, and can bind bnAbs 
but few non nAbs [112,122,123]. Native-like trimers from B41 (subtype B), ZM197M and 
DU422 (both subtype C), and other clades were also engineered using the same SOSIP.664 
design [124-126]. Immunogenicity studies conducted with BG505 and B41 SOSIP.664 
trimers demonstrated autologous Tier-2 nAb responses. However, no heterologous Tier-2 
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nAbs were seen, and the significant portion of antibodies were directed against the 
immunodominant V3 loop [127].  
 In conclusion, these functionally and structurally relevant envelope trimers serve as 
prototype for next generation of immunogens, but improvements are still needed to minimize 
the immune response against non bnAb epitopes and to direct the antibody response towards 
true bnAb epitopes.  
 
Immune complex immunogens 
  Antigen and antibody complexes, referred to as an immune complexes, have been 
used as vaccine immunogens to augment the host immune response against various viral and 
bacterial pathogens, including, infectious bursal disease virus [128,129], hepatitis B surface 
antigen [130,131], dengue virus [132], ebola virus [133,134], porcine parvovirus [135], 
equine herpes virus [136], Clostridium tetani [137], Mycobacterium tuberculosis [138] and 
Francisella tularensis [139].  
  Augmentation of the host immune response has been mainly attributed to the 
interaction of antibody and antigen mediated via Fc receptors.  The interaction of Fc region 
of the antibody with the FcRs on antigen presenting cells (APCs) facilitates the uptake, 
processing and antigen presentation to CD4+ T-helper cells, resulting in more effective T cell 
dependent antibody responses. Deposition of immune complexes on follicular dendritic cells 
increases the antigen concentration and half-life resulting in enhanced B cell proliferation 
and development of germinal centers [140-144].   
  Apart from augmentation of the immune response, antibodies can also alter the 
antigenicity of epitopes on immunogens. Antibodies can shield non-desired epitopes while 
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exposing conserved neutralizing epitopes. This is important, as it has been very difficult to 
direct the immune response towards conserved neutralizing epitopes on HIV-1. Hence, 
immune complex vaccination could represent a new avenue for vaccine development against 
HIV-1. The developments in the field for immune complex vaccination strategy are 
discussed in the next chapter.  
 
Overall Objectives 
     
  The main objective of this study was to evaluate an immune complex vaccination 
strategy for HIV-1 vaccine development. We hypothesize that masking the immunodominant 
hypervariable V3 loop with mAbs might suppress the immune response against this epitope 
and focus the response towards the more highly desired broadly neutralizing epitopes (e.g. 
CD4bs). To test this hypothesis, we made immune complexes of gp120 and anti-V3 loop 
mAb, immunized rabbits with the immune complexes and performed serological 
characterization to confirm the hypothesis. 
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Figures 
               
 
Figure 1. Diagram representing the structure of HIV-1 and envelope glycoprotein 
domains. Gp120 is made up of 5 constant domains (C1-C5, light green) and five 
variable loops (V1-V5, light blue). The signal peptide (SP) is pink. Gp41 (beige) 
comprises of external domain containing MPER (membrane proximal external region, 
red), transmembrane (TM, orange) and cytoplasmic domain (CD). Asterisks represent 
putative glycosylation sites on gp120. 
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Figure 2.  A diagram representing bnAbs discovered from HIV-1 infected patients, 
recognizing different regions on HIV-1 envelope glycoprotein (Adapted from 
[39,40]). Branch shaped structures represents glycans on HIV-1 env glycoproteins 
important for some bnAbs.  
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  CHAPTER II  
 EVALUATION OF IMMUNE COMPLEXING VACCINE STRATEGY FOR HIV-1 
BY MASKING GP120 V3 LOOP  
 
Abstract 
  
 We evaluated an immune complexing strategy for HIV-1 vaccine development due to 
its capacity to augment the host immune response and to reduce immune system access to 
less desired epitopes. We proposed that masking the immunodominant hypervariable V3 loop 
with mAbs might suppress the immune response against this epitope and focus the response 
towards the more highly desired broadly neutralizing epitopes (e.g. CD4 binding site). To test 
our hypothesis, a pilot immunization study was carried out in four rabbits divided in two 
groups. The first group was immunized with gp120 alone, and the second group was 
immunized with an immune complex made of gp120 and the recently reported anti-V3 loop 
rabbit neutralizing mAb 10A37. While not as strong as that observed in gp120 alone, we still 
observed good humoral responses while suppressing the V3-specific total antibody titer in 
immune complex immunized rabbits, as seen by antigen specific antibody titer and fine linear 
epitope mapping. Antibody responses were further evaluated for competition against V3 loop 
monoclonal nAbs to confirm repressed antibody activity towards this epitope, and 
neutralizing ability was assessed to see whether the immune response was being focused 
towards desired critical neutralizing epitopes on HIV-1. Overall, this study demonstrates 
proof of principle and feasibility of immune complexing vaccination strategy.  
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Introduction 
 
 HIV-1 glycoproteins gp120 and gp41 are the sole antigens exposed on the viral 
surface and hence the only targets for vaccine development. There have been many attempts 
at designing vaccines based on subunit protein immunogens using gp120 for eliciting broad 
and potent neutralizing antibodies (bnAbs) against HIV-1. Unfortunately, immunization with 
subunit protein antigens alone has resulted in low antibody titers displaying limited 
neutralization breadth and potency. Also, “rationally-designed” immunogens including eOD-
GT6/eOD-GT8 [1,2] and BG505 SOSIP gp140 [3] failed to induce bnAbs despite high hopes 
and expectations [2,3]. Thus, non-conventional vaccination strategies using novel 
immunogens that can elicit both cell-mediated and humoral immune responses as well as 
focus the immune response towards critical neutralizing epitopes, e.g. CD4 binding site 
(CD4bs), are needed. Therefore, vaccination using immune complexes has particularly drawn 
attention from its ability to modulate the immune response by shielding non-desired epitopes, 
and thus directing immune response towards desired conserved neutralizing epitopes [4].  
  The immune complex vaccination strategy has been somewhat explored for HIV-1. In 
an earlier study, guinea pigs were immunized with immune complexes made of recombinant 
gp120 and human mAb A32, an antibody that does not bind to CD4bs but instead increases 
the exposure of CCR5 binding epitopes on gp120 such that CD4bs is accessible. Although 
the immune complexes were immunogenic, no cross-clade neutralization was seen [5].  A 
second group also evaluated immune complex strategy by inoculating mice with different 
complexes made of gp120 and human mAbs binding different regions on gp120 (like CD4bs, 
C2 and V2 loop) to better target the neutralizing epitopes on the V3 loop [6-11].  
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 In one study, the authors evaluated the immunogenicity of complexes prepared from 
gp120LAI with 654-D, an anti-CD4bs neutralizing human mAb, in mice. High anti-gp120 
antibody titers were observed as compared to uncomplexed gp120, particularly against the 
V3 loop due to antibody induced conformational changes. Unfortunately, the sera 
neutralization ability was limited to homologous viral strains and failed to neutralize 
heterologous strains [11] 
 In an attempt to generate cross-reactive neutralization, they later tested the 
immunogenicity of a complex made up of gp120JRFL/654-D [6]. Since, JRFL strain expresses 
a V3 sequence from a consensus HIV-1 subtype B as compared to the V3 sequence from the 
LAI strain, serum from the immune complex immunized mice demonstrated increased 
neutralization towards homologous and heterologous strains, though the breadth was still 
limited to neutralization sensitive viruses.  
 Env glycoprotein gp120 is well known for its extensive glycosylation, which shields 
conserved neutralizing epitopes thus rendering HIV-1 neutralization resistant [12,13]. Thus, 
researchers have tried to remove N-linked glycans to improve the neutralizing ability [14,15]. 
In one study, authors evaluated the immunogenicity of different immune complexes made of 
gp120s mutants (N448Q and N448E) lacking N–linked glycans and 654-D (N448Q/654-D 
and N448E/654-D) to improve the antibody titers and potency [7]. Both immune complexes 
elicited higher antibody levels towards gp120 and the V3 loop as compared to the wild type 
complex. The elicited nAbs were primarily directed towards V3 loop, and non-nAbs were 
directed against the ID of gp120. Unfortunately, neutralization was limited to homologous 
viral strains and failed to demonstrate cross-clade neutralization, similar to what was 
observed in previous studies.  
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 Thus, all of the immune complex studies elicited high antibody titers against the V3 
loop overall. To understand the mechanism behind this immune modulation of V3 loop 
directed antibody response [9], authors compared the immunogenicity of different complexes 
made from gp120 and mAbs binding to different regions including the C2 region (1006-30), 
the V2 loop (2158) or the CD4bs (654-D). Although all three complexes elicited anti-V3 
nAbs, the gp120/654-D complex was the most potent in terms of antibody titer suggesting 
the specificity of a mAb determines the immunogenicity of the complex.   
 To summarize, while the authors successfully demonstrated the modulation of gp120 
antigenic responses by binding select anti-gp120 mAbs, neutralization breadth and potency 
was limited [8]. This might be due to a major limitation associated with their studies, which 
is using human mAbs to generate immune complexes for evaluation in mice. This might limit 
the full activation of the mouse immune system by hindering B-cell activation. 
 We propose to address this issue by using rabbit mAbs for immune complex 
vaccination in rabbits. We hypothesized that masking the undesirable, immunodominant 
epitopes (eg. V3 loop) with mAbs might suppress the immune response against this epitope 
and indirectly focus the response towards the more highly desired but less immunogenic 
broadly neutralizing epitopes (e.g. CD4bs) as explained in figure 1A. We initially focused 
our efforts on minimizing the immune response against the V3 loop. The V3 loop has been 
known as the principal neutralizing determinant, but elicits type specific nAbs exhibiting 
limited breadth [16,17]. This phenomenon has been observed consistently in both animals 
and humans.  Furthermore, in our experience, we observed high antibody titers directed 
towards V3 loop in rabbits when immunized with a consensus sequence derived (MCON6) 
gp120 only [18], unlike some of the prior immune complexing studies using a specific strain 
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derived gp120 (Visciano 2008). To test this hypothesis, we performed a pilot study in which 
four rabbits were immunized with either gp120 alone or gp120 complexed with a recently 
reported anti-V3 loop rabbit nAb 10A37 [19]. We successfully demonstrated that masking 
the V3 loop with 10A37 significantly diminished the immune response against this epitope, 
suggesting the proof of concept and feasibility of this approach.  
 
Material and Methods 
 
Expression and purification of gp120 
 gp120 protein was expressed and purified using pcDNA*MCON6gp120 plasmid as 
previously described [18]. pcDNA*MCON6gp120 plasmid used for protein expression was 
derived from pcDNA-MCON6gp160 construct (kindly provided by Dr. Beatrice Hahn [20]. 
Briefly, FreeStyle 293-F cells were transfected with pcDNA*MCON6gp120 plasmid using 
293fectin (Invitrogen, Life Technologies) as per manufacture’s protocol. Four days post-
transfection, the 293-F culture medium was harvested and protein was purified using Ni-
NTA agarose beads. The eluted fractions of protein were concentrated using Amicon 
Ultraconcentrator (Millipore) and stored at -80°C until use.  
 
Immune complex formation 
 Immune complexes were prepared at approximately 1:2 molar ratio of gp120 and 
10A37 mAb in PBS by incubating the solution for 2 h at 37 °C. Rabbit mAb 10A37 used in 
the immune complex formation was produced in house [19].  
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Preparation of zinc (Zn)-chitosan adjuvant 
 Zn-chitosan was prepared as described elsewhere [18,21]. Briefly, 2% chitosan 
solution was prepared by dissolving 2 g of chitosan (Sigma, C3646) in 100 ml of 2% acetic 
acid followed by autoclave sterilization. Simultaneously, 0.2 M zinc acetate (Sigma, Z4540) 
solution was prepared and filter sterilized. The 2% (w/v) chitosan solution was diluted 1:1 
using deionized water, and the resulting 1% chitosan solution was mixed 0.2 M zinc acetate 
at 2:3 molar ratio. The suspension was mixed on an end-to-end rocker for 3-4 h at room 
temperature. The mixture was then sonicated using a Branson Digital Sonifier for 5 min 
(63% Amplitude). After sonication, the pH of the solution was adjusted to 12.0-12.5 with 
10N NaOH. Solution was centrifuged at 1000 x g for 10 min. Supernatant was discarded and 
the resulting pellet was vortex with 5-10 ml PBS. More PBS was added to this solution (~50 
ml) and centrifuged at 1000 x g for 10 min for washing the pellet. This wash was repeated 
three times. Finally, the pellet was resuspended in PBS (pH 8). This suspension can be stored 
at room temperature for six months. 
On the day of immunization, the final solution prepared above was vortexed followed 
by centrifuging at 1000 x g for 10 min. The supernatant was discarded and dry weight of the 
pellet was measured using a weighing balance. Antigen and Zn-Chitosan were mixed at 
1:1000 w/w ratio at room temperature for 3 h on an end-to-end rocker prior to immunization 
[18]. 
 
Rabbit immunization and bleeding 
 Four female New Zealand White rabbits (2.5-3 kg; Charles River) were immunized 
subcutaneously with either 100 μg of gp120 protein alone or 100 μg of gp120 protein in 
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complex with 250 μg 10A37 mAb (1:3 molar ratio) on weeks 0, 3, 6 and 9 as shown in Fig. 
1B. Due to low antibody titers seen after the first and second immunizations, antigens were 
supplemented with Zn-chitosan onwards from the third immunization as described above. 
Rabbits were bled two weeks after each immunization, except after fourth immunization 
where animals were bled after eight days instead of two weeks (Fig. 1B). All of the studies 
conducted were approved by IACUC at Iowa State University. 
 
Enzyme-linked immunosorbent assay (ELISA) with protein or overlapping peptides 
 ELISAs were performed as previously described [18,19,22]. For determination of 
antibody titers, gp120 and V3 loop peptide were coated at 30 ng and 100 ng per well 
respectively onto 96-well Nunc-Immuno plates using an antigen coating buffer (15 mM 
Na2CO3, 35 mM NaHCO3, 3 mM NaN3, pH 9.6) at 4°C overnight. For linear epitope 
mapping, 100 ng per well of 15-mer linear overlapping peptides were coated similarly.  
 The next day, uncoated surfaces were blocked with 200 μl of a blocking buffer (PBS, 
pH 7.4, containing 2.5% skim milk and 5% calf serum) and incubated for 1 h at 37°C.  Wells 
were subsequently washed five times with a wash buffer (PBS containing 0.1% Tween 20) 
using a Biotek automated plate washer.  
 For antibody titer, all rabbit sera were serially diluted in blocking buffer as indicated, 
and 100 µl was added to each well.  For the V3 linear epitope mapping, all the rabbit sera 
were diluted 1:100 with blocking buffer (except after first immunization, where 1:50 dilution 
was performed), and 100 μl was added to each well.  The plates were incubated for 2 h at 
37°C. Wells were washed ten times as described.  
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 Plates were incubated for 1 h at 37°C after addition of 100 μl of secondary antibody 
(goat anti-rabbit conjugated with horseradish peroxidase (HRP), Pierce; 1:3000 dilution with 
blocking buffer). Wells were washed ten times again followed by addition of 100 μl TMB 
HRP-substrate (Bio-Rad). The reaction was stopped after 10 min by addition of 50 μl of 2N 
H2SO4, and the plates were read at 450 nm on a microplate reader (Versamax by molecular 
devices). All assays were done in duplicate. 
 The 15-mer overlapping peptide set for gp120 based on an M group consensus 
sequence (CON-S) was obtained from the NIH AIDS Reagent Program (Cat# 9487). V3 
peptide based on the MCON6 sequence (H-
TRPNNNTRKSIHIGPGQAFYATGEIIGDIRQAH-OH) was synthesized commercially by 
CHI Scientific (Maynard, MA).  
 
Biotinylation of 10A37 mAb 
 Biotinylation of 10A37 mAb was performed using EZ-LinkTM Sulfo-NHS-LC-
Biotinylation kit (Pierce, 21435) according to the manufacture’s protocol. Briefly, 10mM 
Sulfo-NHS-LC-Biotin solution was prepared just before the use. 6.7 μl of 10 mM Sulfo-
NHS-LC-Biotin solution was added to the 0.5 mg of 10A37 mAb solution (in 1X PBS). The 
reaction was incubated for 1 h at room temperature with end-to-end mixing. Excess biotin 
from the solution was removed by using a ZebaTM Desalt Spin Column. The column was 
prepared by pre-spinning the column at 1000 x g for 2 min. Storage buffer was discarded, 
and the column was washed three times with 2.5 ml 1X PBS by centrifuging at 1000 x g for 2 
min. The column was placed into a new 15 ml collection tube and the 10A37 mAb solution 
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was applied on the top. The column was centrifuged at 1000 x g for 2 min. The collected 
flow-through is the purified biotinylated 10A37 mAb.  
 
Competition assays 
 Competition assays were performed by modifying the previously described ELISA 
protocol and as described elsewhere [18,19,22].  As before, gp120 and V3 loop peptide were 
coated onto 96-well plates at 30 ng and 100 ng per well respectively. Uncoated surfaces were 
subsequently blocked and washed. Rabbit serum was diluted in 1:5 in blocking buffer. This 
initial dilution was then subjected to two-fold serial dilutions. B10A37 and 10A3 mAbs [19] 
were diluted to a concentration of 120 ng/ml in blocking buffer for competition on gp120.  
For competition on V3 loop peptide, B10A37 was diluted to a concentration of 2 μg/ml.  50 
μl of the diluted antibody was added to each well along with 50 μl of the serially diluted 
rabbit sera.  Hence the final mAb concentration was 60 ng/ml and 1 μg/ml in each well, for 
the competition on gp120 and V3 loop peptides respectively and the starting serum dilution 
was 1:10. The plate was briefly mixed on a plate shaker and then incubated at 37°C for 90 
min. Wells were washed ten times.  The plates were incubated for 1 h at 37°C after addition 
of 100 μl of secondary antibody.  For competition assays with B10A37 mAb, the secondary 
antibody used was anti-streptavidin HRP conjugated (Pierce); diluted 1:10000 in the 
blocking buffer. For competition assays with 10A3 mAb, rabbit anti-human Fc HRP 
conjugated (Pierce); diluted 1:3000 in the blocking buffer was used. Plates were again 
washed ten times. Detection was performed as described above for the standard ELISA.  
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Neutralization assays 
 Virus neutralization assays were performed using single cycle HIV-1 pseudovirus 
infections of TZM-bl cells by as described elsewhere [18,19,23-25]. Briefly, test rabbit sera 
were heat inactivated by incubating in pre-equilibrated water bath at 56°C for 1 h.  11 μl of 
heat inactivated rabbit sera were diluted in 100 µl of cell culture media (10% DMEM/FBS) 
followed by a three-fold serial dilutions. 50 µl of diluted rabbit sera were mixed with 50 µl of 
200 TCID50 (50% tissue culture infectious dose) of the viruses. Hence the final dilution range 
of the rabbit sera was 1:20 through 1:43740. Plates were incubated at 37°C for 1h.  After 
incubation, 1 x 104 TZM-bl cells in 10% DMEM/FBS containing DEAE-dextran (10 µg/ml 
final concentration) was added to the each well. Plates were incubated at 37°C for 48 h. 
Following a 48 hr-incubation, 100 µl of culture medium was removed from each well 
followed by addition of 100 µl of Bright-Glo reagent (Promega, prepared as per 
manufacturer’s protocol). Plates were incubated for 2 min at room temperature cells to allow 
cell lysis followed by pipetting up and down (at least twice) for complete mixing. 150 µl 
from each well was transferred to the corresponding well in a 96-well black solid plate. 
Relative luminescence units (RLU) were measured using a Synerge 2 luminometer. Percent 
neutralization was determined by calculating the difference in average RLU between test 
wells (cells plus test sera) and cell control wells (cells only), dividing this result by the 
difference in RLU between virus control (cells plus virus) and cell-control wells, subtracting 
from 1, and multiplying by 100. 
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      Results 
 
Comparative antigen-specific antibody titers from gp120 and immune complex 
immunized animals 
  Antibody levels were assessed by ELISA against gp120. Animal sera obtained two 
weeks after each immunization was used, except after the fourth immunization when rabbits 
were bled 8 days after. Serum collected prior to immunization (designated as “preimmune”) 
was used as a negative control.  As shown in Figure 2, antibody levels increased 
subsequently with each immunization in both gp120 alone and immune complex groups. 
Although the antibody titers were weak after the first two immunizations which did not 
include additional adjuvants (Figure 2A and B), end point titers reached >105 after the third 
immunization in gp120 alone group and >104 in the immune complex vaccinated group when 
zinc chitosan was used as an adjuvant (Figure 2C).  Antibody titers did not further increase 
after the fourth immunization (Figure 2D).  
 
Antibody responses against the V3 loop in gp120 and immune complex immunized 
animals 
  To determine the efficiency of V3 loop masking, antibody levels post second, third 
and fourth immunizations were assessed by ELISA against a consensus sequence V3 loop 
peptide. Due to overall low antibody titer after the first immunization (Figure 2A), antibody 
level against V3 loop was not evaluated for this timepoint. As shown in Figure 3, antibody 
levels in the gp120 alone group was very low after the second immunization (Figure 3A) but 
increased over 10 fold after the third immunization (Figure 3B) and remained constant after 
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the fourth immunization (Figure 3C). As predicted, the antibody titer in immune complex 
group remained comparatively low throughout the immunization course (Figure 3A-C), 
suggesting that the V3 loop was efficiently masked.  
 
Linear epitope mapping analysis using V3 loop peptides 
  To better characterize the immune response, animal sera were evaluated for reactivity 
against 15-mer linear overlapping peptides spanning the entire length of the V3 loop. The V3 
loop peptide (TH33) was used here as a positive control. As shown in Figure 4A, animals 
from both groups reacted very weakly to the peptides after the first immunization. This is 
likely due to the overall low antibody titers seen after first immunization (Figure 2A). 
 Animal sera after the second immunization from both groups also demonstrated very 
weak reactivity against the peptides (Figure 4B). Only rabbit#2 (R2) from gp120 alone 
group was slightly reactive to the V3 peptide (OD=0.5). This is surprising as both the 
animals from the gp120 alone group exhibited weak binding of the V3 loop (Figure 3A), 
but only R2 showed reactivity in the peptide ELISA.  
 Animal sera from gp120 alone group after third immunization showed significant 
reactivity toward V3 loop peptides (Figure 4C).  Rabbit #1 (R1) favored peptides 9047, 
9049, and V3 (TH33); while R2 showed significant reactivity against 9047 and V3 (TH33) 
as well as weak binding to 9046. This difference in reactivity might be due to animal-to-
animal variation in the immune response. On the other hand, the two rabbits from the 
immune complex group did not react to any peptides spanning the V3 loop. This result is 
again corroborated by the weak antibody titer against the V3 loop in immune complex 
group after the third immunization (Figure 3B). 
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  The reactivity towards the V3 loop peptides increased after the fourth immunization 
in gp120 only group (Figure 4D). The overall binding pattern was similar to what was 
observed after third immunization (Figure 4C). Oddly, R2 showed higher reactivity to the 
V3 (TH33) peptide after the fourth immunization as compared to R1, which is opposite to 
the after third immunization timepoint (Figure 4C). As expected, animals from the immune 
complex group did not bind any peptide except weak binding to 9047 (R2) and 9048 (R1). 
Overall, linear epitope mapping also demonstrated the suppression of antibody response 
towards V3 loop in immune complex immunized animals.  
 
 Competition assays with V3 loop rabbit nAb 10A37 
  To evaluate the efficient masking of V3 loop and repression of the antibody response 
towards this epitope, competition assays were performed on gp120 using V3 loop rabbit nAb, 
10A37 (Yali Plos one ref). Since 10A37 was the antibody used for immune complexing, it 
was important to determine whether animal sera elicited antibodies which can compete 
with10A37 mAb.  To perform the competition, 10A37 was biotinylated (B10A37) to prevent 
the cross reaction of rabbit antibodies with the human Fc region. Animal sera post second, 
third and fourth immunizations from the two groups were used (Figure 5). 
  As shown in Figure 5A, animal sera post second immunization, from both groups did 
not compete against B10A37. This might be due to the low antibody titers observed against 
gp120 as well as the V3 loop (Figure 2B and 3A). 
  Competition increased after third immunization (Figure 5B). R1 from gp120 alone 
group showed significant competition against B10A37 as compared to R2, which showed 
weaker competition (Figure 5B). This correlates with the results from linear epitope mapping 
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post third immunization (Figure 4C) where R1 from gp120 alone group mounted a stronger 
immune response against 9047, 9049 and whole V3 loop peptides as compared to R2. 
Interestingly, R1 from immune complex group exhibited strong competition against B10A37 
as compared to R2, which showed almost no competition (Figure 5B).   
  Similar results were observed after the fourth immunization. But this time, R2 
showed strong competition from gp120 only group as compared to R1, which showed no 
competition (Figure 5C) thus opposite to what was seen after third immunization.  This result 
may not be entirely unexpected, as the strength of the V3 peptide response for these animals 
also slightly reversed between the third and fourth immunizations  (Figure 3C and 4D). 
However, there was no significant difference in the antibody responses in both rabbits against 
V3 peptide (TH33) (Figure 4D), so it is somewhat unexpected that only R2 showed strong 
competition.  
  Surprisingly, both the animals from immune-complex group demonstrated strong 
competition (Figure 5C), as we hypothesized there would be no competition in the immune 
complex animal group. One possibility was that the V3 loop was masked with different 
efficiency in the two rabbits due to animal-to-animal variation which can affect the stability 
of the immune complex (Figure 5B). But strong competition in both these rabbits post fourth 
immunization suggests otherwise (Figure 5C). It is also possible that antibodies elicited in 
response to the immune complex are binding in the vicinity of 10A37 epitope thus the V3 
loop, which therefore prevents the binding of 10A37 mAb due to steric hindrance offered by 
the competing antibodies. Also, these competing antibodies might exhibit conformational 
dependent binding, which is not detectable by linear epitope mapping in the immune 
complex group.  
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  To understand the competition seen in the immune complex group, we performed a 
similar competition assay with B10A37 but instead on the V3 loop peptide (TH33) rather 
than gp120 (Figure 6). We considered that the V3 loop might be exposed differently on 
gp120 as compared to the peptide alone, which might affect the binding of antibodies elicited 
in the immune complex sera. As we predicted, no competition was seen after second and 
third immunization (Figure 6A and 6B) in both of the groups. After the fourth immunization, 
animals from the immune complex group exhibited slightly stronger competition compared 
to the gp120 only group (Figure 6C), but the competition was weak as compared to that seen 
on gp120 (Figure 5C). This is in accordance with our prediction that antibodies elicited in the 
immune complex sera might be binding in the vicinity of either the 10A37 epitope or the V3 
loop in general, preventing binding of 10A37. Moreover, this competition was primarily 
observed on the whole protein (gp120) as compared to smaller peptide (V3 loop) due to the 
presence of more potential epitopes on the larger protein.  
 
Competition assays with V3 loop rabbit nAb 10A3 
  We also performed competition assays with a second V3 loop nAb, 10A3, to confirm 
the repression of antibody response against V3 loop (Figure 7). Since 10A37 and 10A3 have 
overlapping binding epitopes [19], we expected to see no competition in immune complex 
group of animals. As expected, immune complex group of animals did not compete after the 
second, third and fourth immunizations (Figure 7A-C). R1 from gp120 only group possessed 
stronger competition as compared to R2 post second immunization (Figure 7B). This is 
similar to the result seen for competition against B10A37 (Figure 5B). After the fourth 
immunization, R2 from gp120 only group demonstrated significantly increased competition 
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(Figure 7C).  This might be due to the antibody titer increase against V3 loop peptides in R2 
post third immunization as seen in Figure 4C. Overall, competition ELISA also demonstrated 
repressed antibody response towards the V3 loop peptide suggesting proof of this technique. 
 
Neutralizing activity of the immune complex sera 
  The potency and breadth of animal sera from two groups were assessed using a 
standard TZM-bl neutralization assay against neutralization sensitive Tier-1 pseudoviruses 
from different clades and neutralization resistant Tier-2 pseudovirus (Figure 8).  
Neutralization was only tested for animal sera post fourth immunization. As shown, animal 
sera from gp120 alone group could effectively neutralize SF162.LS and MW965.26 (Figure 
6B and 6C). Weak neutralization was seen against BaL.26 (Figure 6A) and no neutralization 
was seen against Q23.17 and pBJOX 2000. This is consistent with our previous study [18]. 
On the other hand, immune complex sera failed to neutralize all tested pseudoviruses. Prior 
work in this laboratory demonstrated that most of the neutralizing antibodies elicited by the 
gp120 antigen are towards the V3 loop [18], and thus masking of this epitope likely 
prevented the induction of such antibodies.  
 
Discussion 
In this study, we evaluated an immune complex vaccination strategy for HIV-1 to focus the 
antibody response towards critical neutralizing epitopes on gp120. We evaluated the 
differences in the immune response elicited in rabbits vaccinated with gp120 alone versus 
an immune complex comprised of gp120 and rabbit anti-V3 loop nAb 10A37 using 
different immunological assays. 
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  While we hypothesized that higher antibody titers would be elicited in the immune 
complex group from the known augmentation to the immune response, to our surprise, the 
total antibody titer in gp120 only group was nearly 10 fold higher than the immune 
complexed group (Chapter 2, Figure 2). The exact reason behind this phenomenon is 
unknown.  However, it is well established that most of the antibody response against gp120 
is directed towards the immunodominant V3 loop [16-19,22], and hence masking of a V3 
epitope could reduce the total antibody titer observed in the immune complex. Irrespective 
of this, the total antibody titer in gp120 group remained low throughout immunizations as 
compared to a previous study where rabbits were immunized at all time points with gp120 
on zinc chitosan [18]. In that study, the total antibody titers reached >105 just after a single 
immunization, whereas our titers were very low.  Following the second immunizations, 
titers in the original study reached 2x106, while in this study titers remained steady at 
1x105.  One important thing to note is that in the current study we started using zinc 
chitosan as an adjuvant only after the second immunization as compared to our previous 
study where zinc chitosan was used throughout [18]. Lack of adjuvant during the first two 
immunizations might have also reduced the total antibody immune response.   
 Apart from the total antibody titer, there was also a clear difference in the immune 
response against the V3 loop in the two groups.  As predicted, the antibody response 
against the V3 loop was diminished (~10 fold) as compared to gp120 only group. This 
suggests the successful masking of the V3 loop by mAb and the feasibility of an immune 
complex vaccination strategy. Fine epitope mapping performed by linear peptide ELISA 
also corroborated our finding that an mAb can modulate the immune response at the 
epitope level as the immune complex sera did not recognize any V3 loop peptides 
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throughout the immunizations. On the other hand, gp120 immunized animals showed a 
strong immune response against V3 loop peptides, which is in agreement with our previous 
studies [18,22].  
 Unfortunately, the information provided by linear epitope mapping is limited and 
cannot be used for assessing antibodies targeting the non-contiguous, conformation 
dependent epitopes. Although the antibody response in immune complex vaccinated rabbits 
was diminished against the V3 loop, there still might be antibodies recognizing 
conformational epitopes not detectable by linear overlapping peptides. As such, we 
performed competition assays on gp120 with V3 loop neutralizing mAbs 10A37 and 10A3, 
isolated and characterized in our laboratory [19]. Although immune complex sera did not 
compete with 10A3, strong competition against 10A37 mAb was seen. This was surprising, 
as we had predicted there would be no competition for either antibody due to masking of 
the V3 loop, of which 10A37 and 10A3 share an overlapping epitope. We also observed 
significant differences in competition amongst the two animals within a group.  For 
example, in the immune complex group, R1 showed strong competition after the third 
immunization, but both rabbits showed strong competition after the fourth immunization. 
Whereas in the gp120 only group, both rabbits competed after the third immunization, but 
only R1 showed competition after the fourth immunization. Animal-to-animal variations in 
the immune response might account for this difference. Also, such animal-to-animal 
variations may induce the immune complex to disassociate more quickly in one animal 
versus the other, thereby permitting the elicitation of 10A37 like antibodies following 
complex dissolution.  
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 Stronger competition in the immune complex group might also arise from the 
antibodies binding in the vicinity of the 10A37 epitope or V3 loop, offering steric 
hindrance to 10A37 mAb preventing its binding. This possibility is corroborated by the 
lack of competition after the second and third immunizations and the very weak 
competition seen on the V3 loop peptide as compared to gp120. Variable loops are highly 
dynamic and in the structural context of the entire gp120 glycoprotein, the V3 loop is likely 
exposed differently as compared to the truncated peptide presented without the other 
structural elements of gp120. This can make a huge impact on antibody dynamics. Gp120 
immunized animals demonstrated stronger competition against 10A3 as compared to 
10A37, which might be due to fact that antibodies binding an N-terminal V3 epitope like 
10A3 are more prevalent as compared to those binding more C-terminal epitopes like 
10A37 [18,19,22]. 
 Unfortunately, immune complex vaccinated animals failed to demonstrate 
neutralizing activity against Tier-1 as well as Tier-2 pseudoviruses, while gp120 
immunized sera neutralized SF162.LS and MW965.26 (Tier-1 sensitive viruses). We 
previously demonstrated that most of the neutralizing antibodies in the gp120 immunized 
animals are directed towards the V3 loop and have limited breadth [18]. Therefore, 
masking the V3 loop epitope may have caused a significant reduction in the neutralizing 
activity in immune complex sera.  
 It is difficult to compare our results with other immune complex studies in HIV-1. 
Authors from previous studies have masked CD4bs in order to increase the 
immunogenicity of neutralizing epitopes on V3 loop [6-8,10,11,26]. We, on the contrary, 
masked the V3 loop to direct the immune response towards other neutralizing epitopes (e.g 
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CD4bs). While other authors reported higher antibody titers in immune complex group as 
compared to gp120 only group, which suggested that immune complexes augment the 
antibody response, we saw the opposite results. They also reported neutralizing activity 
against Tier-1 sensitive viruses as compared to our study where no neutralization was seen. 
We hypothesize that it might be more challenging to target the CD4bs as compared to 
theV3 loop by masking using a single mAb because different mAbs can have different 
effects on antigenic modulation. Also, difference in the animal model system (mice versus 
rabbits) and the choice to use species matched versus non-matched mAbs can have an 
impact on the final results.  
 Thus, our findings indicate that although the immune complex vaccination strategy is 
an effective way of modulating immune response against desired epitopes, further 
improvement is required to achieve final goal of eliciting broadly neutralizing antibodies. 
These possibilities will be further discussed in the final chapter.  
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     Figures 
 
   
Figure 1. [A] Diagram showing the predicted difference in the immune responses 
directed against uncomplexed versus immune complexed gp120. When gp120 is 
uncomplexed, the immune response is directed towards different epitopes on gp120, 
including the V3 loop, as shown by the green arrows and antibodies. On the right, we 
hypothesized that when the V3 loop is masked with mAb (shown in red), the immune 
response will be better directed towards conserved neutralizing epitopes (e.g CD4bs) 
and other sub-dominant epitopes, as shown by the larger green arrows. [B] Timeline 
for rabbit immunization and bleeding.  
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Figure 2. Total antibody titer against gp120 as determined by ELISA. Anti-sera 
obtained after the [A] first, [B] second, [C] third and [D] fourth immunizations were 
used.  “Preimmune” is the serum sample collected prior to the beginning of 
immunizations and used here and throughout as a negative control. A450 represents 
absorbance value at 450nm.  
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Figure 3. Total antibody titer against the V3 loop as determined by ELISA. Anti-sera 
obtained after the [A] second, [B] third and [C] fourth immunizations were used.
  
Figure 4. Linear epitope mapping by ELISA using 15mer overlapping peptides. Sera obtained after the [A] first, [B] second, 
[C] third and [D] fourth immunizations were used.  
5
5
 
 
56 
 
Figure 5. Sera competition against biotinylated 10A37 on gp120. Anti-sera obtained 
after the [A] second, [B] third and [C] fourth immunizations were used. The value on 
x-axis represents serum concentration (1/dilution factor).  
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Figure 6. Sera competition against biotinylated 10A37 on V3 loop peptide. Anti-sera 
obtained after the [A] second, [B] third and [C] fourth immunizations were used. The 
value on x-axis represents serum concentration (1/dilution factor). 
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Figure 7. Serum samples after the  [A] second, [B] third and [C] fourth immunizations 
were tested for competition against 10A3. The value on x-axis represents serum 
concentration (1/dilution factor).
 Figure 8.  Neutralizing activity of the sera against Tier-1 and Tier-2 viruses from different clades. Serum sample obtained 
after the fourth immunization was tested.  
5
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            CHAPTER III 
 
GENERAL CONCLUSIONS 
 
HIV-1 infection has caused a staggering number of deaths across the globe and 
created a huge socioeconomic impact. Despite decades of exhaustive research efforts, an 
effective vaccine against HIV-1 stills remains elusive and a top priority. A universal vaccine 
targeting HIV-1 has been unsuccessful due to an extensive amount of variation presented by 
virus to the host immune system [1-3]. In addition to this, HIV-1 has also evolved various 
immunological evasion strategies, causing the virus to quickly escape the immune system [4-
7]. This leaves the host immune system severely impaired, which under such circumstances 
become highly prone to so called “opportunistic infections”. Discovery of potent anti-
retroviral drugs and highly active anti-retroviral therapy (HAART) has made the disease 
more manageable than before [8]. Unfortunately, current therapies have been unsuccessful at 
eradicating the virus completely from the host, causing virus levels to rebound in the plasma 
as soon as the treatment is stopped [9]. Thus, patients are supported on lifelong therapies that 
lead to potential side effects and enormous health care costs. Thus, an effective vaccine 
might be the most cost effective way of preventing HIV-1 infection. The discovery of bnAbs 
in certain HIV-1 infected patients has provided hope that an actual HIV-1 vaccine might be 
possible.  
 In the quest for an effective vaccine, researchers across the globe have designed and 
evaluated various vaccine immunogens based on the structural knowledge of HIV. The 
envelope glycoproteins gp120 and gp41 are the sole targets available for vaccine design and 
are widely exploited in various immunogen designs [10]. Unfortunately, all such 
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immunogens tested in clinical trials were unsuccessful at inducing effective responses against 
HIV-1. We evaluated a non-conventional, immune complex vaccination strategy for HIV-1 
by masking the immunodominant V3 loop on gp120 with a rabbit mAb. Our findings 
indicate that mAbs can successfully modulate the immune response against desired antigenic 
epitopes. Although we did not see any neutralizing activity in animal sera, this study 
provided proof of principle and feasibility of the approach. Further improvement is required 
to elicit bnAbs by vaccination.  
 
           Future Directions 
 
The studies in this thesis evaluated an initial attempt at an immune complex 
vaccination strategy for HIV-1 vaccine by suppressing the response against immunodominant 
V3 loop and potentially focusing the immune response towards critical bnAb epitopes.  
Although we successfully masked the V3 loop as shown by diminished immune response 
towards this epitope, we have not established where the immune response is actually 
targeted. Future experiments including extended linear epitope mapping using overlapping 
peptides covering the entire length of gp120 might provide some answer. Also, competition 
assays using CD4bs bnAbs can test whether more of the immune response is being directed 
towards the CD4bs in immune complexed animals versus gp120 alone. There is a possibility 
that we might not have targeted CD4bs since animal sera failed to neutralize Tier-1 as well as 
Tier-2 viruses. We therefore might need to mask additional epitopes direct immune response 
towards conserved sites like CD4bs.  One possible solution is masking additional 
immunodominant epitopes because in the current study we only evaluated one mAb for 
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making immune complexes and its effect on antigenic modulation. Recently we characterized 
a large panel of rabbits mAbs isolated from an animal immunized with gp120 alone, which 
bind to different epitopes [11]. These epitopes include several which were observed to be 
immunodominant (C1, C2, C5, V5). Immunization with cocktails of different immune 
complexes targeting different epitopes might be an alternative strategy. 
 Irrespective of these measures, immune complexing using gp120 might never elicit 
broadly neutralizing antibodies due to the presence of the large number of immunodominant, 
but non neutralizing or weakly neutralizing “decoy” epitopes that distract the immune system 
from mounting a suitable bnAb response.  Furthermore, it is suggested that in particular the 
germline B cell receptors may not effectively interact with the CD4bs bnAb epitope on native 
env structures such as our gp120 antigen [12]. We would like to evaluate this strategy using 
alternate immunogens like BG505 SOSIP gp140 [13] and eOD-GT8 [14], which are 
optimized for better presentation of bnAbs epitopes. Although immunogenicity studies using 
these immunogens have not yielded impressive results so far [14,15], we propose to improve 
these immunogens by antibody based antigenic modulation. In addition to the previously 
mentioned gp120 derived panel [11], we are also currently screening B-cell hybridomas 
generated from animals immunized with eOD-GT6 and BG505 SOSIP, for finding potential 
mAbs recognizing these proteins. Thus we have necessary resources to test alternate 
immunogens with immune complexing in the future. 
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     Abstract 
 
We recently reported induction of potent, cross-clade neutralizing antibodies (nAbs) 
against HIV-1 in rabbits using gp120 based on an M-group consensus sequence.  Competing 
antibodies to VRC01 and PGT121 for binding gp120 were also detected.  To better 
characterize these antibodies, 93 hybridomas were generated, which represent the largest 
panel of monoclonal antibodies (mAbs) ever generated from a vaccinated rabbit.  The single 
most frequently recognized epitope of the isolated mAbs was at the very C-terminal end of 
the protein, followed by the V3 loop.  Although we did not isolate any VRC01-competing 
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mAbs, all seven anti-V3 loop mAbs competed with PGT121.  Two of the V3 mAbs (10A3 
and 10A37) exhibited neutralizing activity.  In contrast to 10A3 and most other anti-V3 
nAbs, 10A37 was atypical with its epitope positioned more towards the C-terminal half of 
the loop.  To our knowledge, 10A37 is the most potent and broadly neutralizing anti-V3 loop 
mAb induced by vaccination. 
 
Introduction 
 
A critical problem for developing a vaccine against human immunodeficiency virus 
type 1 (HIV-1) is the difficulty in inducing broadly neutralizing antibodies (bnAb) against 
the large number of viral variants that exist [1-3].  The envelope glycoproteins gp120 and 
gp41 are the sole HIV-1 antigens on the virion surface targeted by nAbs.  Therefore, 
characterizing the immunogenic and structural features of the HIV-1 envelope is important 
for designing immunogens to elicit bnAbs and to understand the humoral response to HIV-1 
infection [4-6].   
Monoclonal antibodies (mAbs) have been important tools for probing antigen 
structures.  Recent technology developments for antigen-specific single B cell sorting [7,8], 
high-throughput clonal memory B-cell cultures [9] and next-generation sequencing (NGS) 
[10] have enabled isolation of a large number of new bnAbs against HIV-1 from virus-
infected patients [11].  Those bnAbs have defined four major targets on the HIV-1 envelope:  
the CD4 binding site (CD4BS), glycans around N160 along with conserved elements on 
V1/V2, the base of and glycans around the V3 loop, and the membrane-proximal external 
region (MPER) of gp41 (as reviewed in [12,13]).  Recently, epitopes involving both gp120 
and gp41 have been identified as well [14-17]. 
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In contrast to bnAbs isolated from HIV-1 infected humans, envelope-specific mAbs 
generated from vaccinated subjects, either animals or humans, are limited.  Early studies 
isolated many murine mAbs from immunized animals.  However, most did not possess 
significant neutralizing activity [18-23].  Later, Gao et al. reported two mAbs isolated from 
gp140-immunized mice that cross-reacted with all tested envelope proteins, but neither mAb 
neutralized primary HIV-1 pseudoviruses [24].  Derby et al. isolated six anti-gp120 mAbs 
from mice immunized with soluble gp140 [25].  These antibodies could neutralize the 
homologous SF162, and their activities were dependent on the glycosylation patterns of the 
V1, V2 or V3 loops.  However only one anti-V3 mAb displayed cross-clade neutralizing 
activity, which was dependent on the type of V1 loop present on heterologous viruses.  
Recently, Sundling et al. used a non-human primate (NHP) model to evaluate envelope 
immunogens that elicited anti-CD4BS antibodies, isolating a panel of functional mAbs from 
immunized rhesus macaques [26].  However, only eight mAbs were generated that exhibited 
neutralizing activity against a limited number of mostly tier 1 HIV-1 isolates (viz. MN.3, 
HXBc2, SF162 and MW965.26).  The RV144 clinical trial reported an estimated 31% 
protection efficacy, and protection correlated with the presence of anti-V2 loop antibodies in 
immunized individuals [27-29].  Most recently, four V2 mAbs were isolated from RV144 
participants [30].  These mAbs recognized amino acid residue 169, neutralized tier 1 
laboratory HIV-1 strains and mediated antibody dependent cell-mediated cytotoxicity 
(ADCC).  Additionally, two other neutralizing V3 loop mAbs (CH22 and CH23) were 
isolated from the participants in RV135 trial, which showed limited neutralization against tier 
1 strains [31]. 
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Rabbits have been used widely in HIV-1 vaccine studies.  Compared to other animal 
models, rabbits are large enough for collection of sufficient amount of antisera for nAb 
assessment, and can develop long CDR3s [4,24].  Although rabbits have restricted antibody 
germline usage, particularly in the heavy chain [32,33], their immune system is similar 
enough to that of humans [34-38] to allow for assessment of potential nAb induction.  
Furthermore, rabbit hybridomas can be generated to produce mAbs to determine the specific 
characteristics of individual antibodies.  Recently, Chen et al. [39] reported generation and 
characterization of twelve mAbs from HIV-1 Env-immunized rabbits, three of which 
exhibited neutralizing activity. 
We recently reported induction of potent neutralizing antibodies using soluble gp120 
based on M group consensus sequence (MCON6; [40,41]) in rabbits [42].  Although the 
primary neutralizing epitope appeared to be the V3 loop and that neutralizing activity was 
largely against tier 1 virus isolates, the cross-clade neutralizing breadth was substantial.  
Further characterization of antibodies against gp120 in a follow up study revealed that some 
of them could compete with bnAbs VRC01, PGT121, and PGT126 in binding gp120, 
suggesting that the antibodies bound at or near the vicinity of epitopes targeted by these 
bnAbs [43].  
Although we did not succeed in inducing “true” bnAbs using our vaccine regimen, it 
was important to (1) further characterize the nature of potent neutralizing activity against the 
V3 loop, (2) identify target epitopes of antibodies that competed with bnAbs VRC01 and 
PGT121/126, (3) determine immunogenic epitopes of antibodies that failed to exhibit 
neutralizing activity in order to develop better immunogens or immunization strategies, and 
(4) examine maturation pathways of these antibodies.  To achieve these objectives, 
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antibodies will have to be characterized at a clonal level.  In this study, we generated 93 
hybridomas from one of the gp120-immunized rabbits that mounted an unusually strong nAb 
response against a tier 1 Clade AE virus (TH023.6 strain; ID50 >43,740).  To our knowledge, 
this panel of mAbs represents the largest collection of antibodies ever generated from a rabbit 
against HIV-1 gp120.  This report is meant to provide an overview, rather than 
comprehensive characterization of all of the mAbs generated.  It will focus primarily on 
characterization of the V3 loop mAbs. 
 
Materials and Methods 
 
Rabbit immunizations and hybridoma generation 
The gp120 protein vaccine used was derived from pcDNA-MCON6gp160 (kindly 
provided by Dr. Beatrice Hahn [41]).  A more extensive description is detailed in a previous 
publication [42].  The gp120 protein was purified from cell culture supernatant using tandem 
affinity chromatography.  Three female New Zealand white rabbits (2.5-3 kg; Charles River) 
were immunized subcutaneously with gp120 formulated with Zn-chitosan on weeks 0, 3, 9, 
15 and 27 as previously described [42].  One rabbit (gp120-R2) with the highest nAb titer 
was boosted at week 65.  On week 76, the animal was injected intravenously with 1 mg of 
gp120 in PBS.  Four days later, spleen was collected for fusion.  All of the studies conducted 
were approved by IACUC at Iowa State University (#10-09-6772-LM). 
The fusion was performed as previously described [40] with a few minor 
modifications.  Briefly, rabbit splenocytes and the fusion partner cell line 240E-1 (kindly 
provided by Dr. Katherine L. Knight [40]) were fused at a ratio of 2:1 with 50% PEG 1500 
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(Sigma-aldrich P7181).  The hybridomas were selected by growing in media containing HAT 
(hypoxanthine, aminopterin, and thymidine) (Sigma-aldrich H0262).  Hybridoma 
supernatants were collected and screened for gp120 binding by ELISA, and for neutralization 
activity as described below.  Hybridomas that were positive for gp120 binding were cloned 
by limiting dilution, expanded and frozen at -140oC for future use.   
 
ELISA with proteins or overlapping peptides 
ELISAs were performed as previously described [42,43] with some modifications.  
For determination of antibody titer and screening of our hybridoma panel, the indicated 
proteins were coated onto 96-well Nunc-Immuno plates overnight at 4°C at 30 ng per well 
using an antigen coating buffer (15 mM Na2CO3, 35 mM NaHCO3, 3 mM NaN3, pH 9.6).  
For screening hybridomas for the inner domain peptides (ID-P) and fine epitope mapping of 
V3 loop positive antibodies, 15-mer linear overlapping peptides were coated onto 96-well 
Nunc-Immuno Plates overnight at 4°C at 20 pmol per well in the same antigen coating 
buffer.  Uncoated surfaces were blocked with 200 μl of a blocking buffer (PBS, pH 7.4, 
containing 2.5% skim milk and 5% calf serum) for 1 h at 37°C.  Wells were subsequently 
washed five times with a wash buffer (PBS containing 0.1% Tween 20) using a Biotek 
automated plate washer.  For antibody titer, all rabbit sera were serially diluted in blocking 
buffer as indicated in figures, and 100 µl was added to each well.  For the cross reactivity of 
our panel of hybridomas and V3 fine epitope mapping, all the hybridoma supernatants were 
diluted 1:2 with blocking buffer and 100 μl was added to the each well.  For the reactivity of 
hybridomas to ID-P, 100 µl of the hybridoma supernatant was added directly to each well.  
The rest of the procedure was similar to what has been described before [42,43].  All assays 
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were done in duplicate. The 15-mer overlapping peptide set for gp120 based on the M group 
consensus sequence (CON-S) was obtained from the NIH AIDS Reagent Program (Cat# 
9487). V3 and V5 peptides based on the MCON6 sequence (H-
TRPNNNTRKSIHIGPGQAFYATGEIIGDIRQAH-OH and H-GNNSNKNKTETFRPG-OH, 
respectively) were synthesized commercially by CHI Scientific (Maynard, MA).  Peptides 
were coated onto wells at 20 pmol per well.    
 
Neutralization assays 
Virus neutralization assays were done using single cycle HIV-1 pseudovirus 
infections of TZM-bl cells as described elsewhere [42,44,45].  Briefly, heat inactivated rabbit 
sera (56°C for 1hr), hybridoma supernatant or purified IgG was diluted in 100 µl of cell 
culture media (DMEM supplemented with 10% heat inactivated FBS and 1% 
penicillin/streptomycin).  Test samples were diluted over a range of 1:20 to 1:43740 in cell 
culture medium and pre-incubated with virus (~150,000 relative light unit equivalents) for 1 
hr at 37 oC before addition of cells. Following a 48 hr-incubation, cells were lysed and Luc 
activity determined using a microtiter plate luminometer and BriteLite Plus Reagent (Perkin 
Elmer).  Neutralization titers are the sample dilution (for serum) or antibody concentration 
(for sCD4, purified IgG preparations and monoclonal antibodies) at which relative 
luminescence units (RLU) were reduced by 50% compared to RLU in virus control wells 
after subtraction of background RLU in cell control wells.  
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Competition assays 
Competition assays were performed by modifying the previously described method 
[43].  The amount of coating antigen used was 30 ng per well.  Briefly, equal amount of 
hybridoma supernatant was added to equal amount of blocking buffer.  This initial dilution 
was then subjected to two-fold serial dilutions.  Monoclonal antibodies were diluted to a 
concentration of 1 μg/ml in blocking buffer.  50 ul of the diluted antibody was added to each 
well along with 50 μl of the serially diluted hybridoma supernatant.  Hence the final 
monoclonal antibody concentration during the assay was 0.5 μg/ml in each well, and the 
starting supernatant dilution was 1:4.  In order to test competition at a higher concentration, 
50 μl of hybridoma supernatant was added directly with 50 μl of competing antibody (at 1 
μg/ml concentration) to result in the 1:2 dilution.  Antibodies used for competition included 
VRC01 [8], and PGT121 [46].  For competition of purified monoclonal antibody to PGT121, 
10A37 was diluted to a concentration of 6 μg/ml in blocking buffer and then subjected to 
two-fold serial dilutions.  50 µl of the diluted PGT antibody was added to each well along 
with 50 µl of the serially diluted 10A37 antibody.  Hence, the final PGT concentration was 
0.5 μg/ml in each well, and the starting 10A37 concentration was 3 μg/ml.  Another mAb 
(2C2) that was isolated from a rabbit immunized with C-terminal 54 amino acid of gp41 
ectodomain (to be published elsewhere), was used at similar concentrations as a negative 
control.  The rest of the procedure was same as previously described [43].  
 
Cloning of hybridoma antibody genes 
 Total RNA was extracted from hybridomas using the RNeasy Mini kit (Qiagen) using 
the Qiacube automated platform.  Following extraction, RNA samples were treated with 
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DNAse (Invitrogen) to remove genomic DNA. Samples were subjected to cDNA synthesis 
using random hexamers and SuperScript III Reverse Transcriptase (Invitrogen).  Briefly, 2 
μL of random hexamers (Roche) and 2 μL of 10 mM dNTPs were added to 22 μL of DNAse 
treated RNA (equivalent to approximately 3x106 cells).  The mixture was heated to 65oC for 
5 min, then cooled briefly on ice.  Subsequently, 8 μL of 5x First-Strand Buffer, 2 uL of 0.1 
M DTT, 2 uL of RNaseOUTTM (Invitrogen), and 2 uL of SuperScript III were added to the 
mixture.  Reaction was incubated at 25oC for 5 min, 45oC for 45 mins, and 70oC for 15 mins. 
Resulting cDNA was subjected to Ab gene amplification using Platinum Pfx polymerase 
(Invitrogen) according to manufacturer’s recommendations.  Primers for Ab gene 
amplification were based on a previous publication [47].  Primers used for heavy chain 
amplification were 5’- AGGAATTCTGCAGCTCTGGCACAGGAGCTC-3’ and 5’- 
CTCCGGATCCGTCGACAGGACTCACCACCTGAGGAGACGGTGACCA-3’.  Primers 
used for kappa chain amplification were 5’- 
TATCCGTGCACTCCACCATGGACACGAGGGCCCCCACT-3’ and 5’- 
GTTAGATCTATTCTACTCACGACCTTTGACCACCACCTCGGTCCCTCCGCCGAA-3’ 
or 5’- TCACTGGCGGTGCCCTGGCAGGCGTCT-3’ (10A37 only).  Cycling conditions 
were as follows:  Initial denaturation at 94oC for 5 mins; followed by 35 cycles of 94oC for 
30 sec, 68oC for 1.5 mins; final extension at 68oC for 7 mins; hold at 4oC.  Resulting PCR 
products were directly sequenced.  Alternatively, the 10A3 and 10A37 hybridomas were 
subjected to Ab gene specific cDNA generation and PCR using the SuperScript III One-Step 
RT-PCR System (Invitrogen), using the primers described. 
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Heavy and light chain sequence analysis 
 Heavy and kappa chain sequences were analyzed with IMGT/V-quest [48] to 
determine germline usage, mutations present, and CDR domain lengths.  Protein sequence 
alignments were performed with Clustal Omega (www.ebi.ac.uk/Tools/msa/clustalo/). 
 
Expression and purification of 10A3 and 10A37 antibodies 
Antibody variable regions were cloned into either the pFUSEss-CHIg-hG1 and 
pFUSEss-CLIg-hk (human conserved regions, 10A3 heavy and kappa chain respectively, 
InvivoGen) or pFUSEss-CHIg-rG and pFUSEss-CLIg-rk2 (rabbit conserved regions, 10A37 
heavy and kappa chain respectively, InvivoGen) vectors for expression.  Heavy chain primers 
for 10A3 were 5’- ACGTGAATTCGCAGGAGCAGCTGGAGGAGTC-3’ and 5’- 
GACCGCTAGCTGAGGAGACGGTGACCAG-3’.  Kappa chain primers for 10A3 were 5’- 
GGTCGAATTCAGCTCAAGTGCTGACCCAG-3’ and 5’-
GACCCGTACGTTTGACCACCACCTCG-3’.  Heavy chain primers for 10A37 were 5’-
ACGTGAATTCGCAGGAGCAGCTGGTGGAGTC-3’ and 5’-
GCCCACTCGAGACGGTGACCAGGGTGCCTGGGC-3’.  Kappa chain primers for 10A37 
were 5’-GGCGAATTCAGCCCTTGTGATGACCCAG-3’ and 5’-
CGAGCTAGCTCGCTCTAACAGTCACCCCTATTG-3’.  Restriction sites introduced for 
subsequent cloning are underlined.  The heavy chain PCR product for 10A3 and vector were 
digested with EcoRI and NheI.  The kappa chain PCR product for 10A3 and vector were 
digested with EcoRI and BsiWI. The heavy chain PCR product for 10A37 and vector were 
digested with EcoRI and XhoI.  The kappa chain PCR product for 10A37 and vector were 
digested with EcoRI and NheI.     
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Standard ligation protocols generated the final 10A3 rabbit-human chimera and 10A37 rabbit 
expression vectors, and sequencing confirmed an in frame variable region fusion. 
For 10A3 and 10A37 antibodies purification, heavy and kappa chain constructs were 
co-transfected into freestyle 293F cells with 293fectin (Invitrogen).  The supernatant was 
collected 5 days after transfection and clarified by centrifugation, followed by immobilized 
protein A affinity chromatography purification (Pierce).  Purified 10A3 and 10A37 was 
dialyzed in PBS (pH 7.4), aliquoted and then stored at -800C.   
 
Results 
 
Antibody responses against gp120 booster immunization following an extended resting 
period 
In previous reports, we described antibody responses against monomeric MCON6 
gp120 in rabbits following five immunizations over a period of about 29 weeks [42,43].  We 
selected one of the animals (rabbit #2) that had mounted strong neutralizing activity against 
Clade AE, tier 1 TH023.6 isolate (ID50 >43,740 in TZM-bl assay), as well as some activity 
against tier 2 isolates, for long-term evaluation.  The animal was allowed to rest for 38 weeks 
and immunized a 6th time on week 65 (Fig. 1A).  A serum sample was collected just prior to 
immunization (referred to as “pre 6th”) to assess durability of antibody responses and to 
determine the baseline level, and two weeks post immunization on week 67 (referred to as 
“post 6th”) to evaluate recall responses. 
Antibody levels were monitored by ELISA using the autologous antigen (Fig. 1B).  A 
serum sample collected two weeks after the fifth immunization (on week 29) was used for 
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direct comparison.  A serum from an age-matched, mock-immunized rabbit (designated as 
“PBS”) was used as a negative control.  Results showed that the antibody level declined 
approximately 7-8 fold during the 38 weeks of resting period after the fifth immunization 
(estimated half-life of about 12.7 weeks).  However, after the sixth immunization, the 
antibody level increased back to the level achieved after the fifth immunization, which 
appeared to be the maximum achievable antibody titer.  Immunogenic linear epitope profile, 
as determined by ELISA using 15mer overlapping peptides, was similar to that observed 
after the fifth immunization (data not shown; [43]).   
As described previously [42,43], the potency of neutralizing activity induced in this 
rabbit was quite substantial, albeit largely against tier 1 viruses.  More interestingly, 
antibodies that could compete with bnAbs VRC01 as well as PGT121 and PGT126 in 
binding gp120 were observed [43].  Although we did not detect broadly neutralizing activity 
against tier 2 viruses, we hypothesized that better understanding of gp120-induced antibodies 
would allow for better design of future immunogens as well as immunization strategies.  Our 
goal was to characterize these antibodies at a monoclonal level.  Because such 
characterizations are time consuming and laborious, we first examined whether the rabbit 
maintained nAbs as well as VRC01- and PGT121-competing antibodies before undertaking a 
detailed molecular analysis.       
Neutralizing activity of sera from pre- and post-6th immunization was tested against 
tier 1A viruses from Clade B (MN.3 and SF162.LS) and Clade C (MW965.26).  Serum 
sample after the 5th immunization was also tested for comparison.  As expected, neutralizing 
activity declined against all three viruses during the resting period between the fifth and the 
sixth immunization (Fig. 1C), similar to the decline observed in antibody titers (Fig. 1A).  
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Upon the sixth immunization, serum neutralization increased, but remained at a slightly 
lower level than what was observed after the fifth immunization.  It should be noted that 
significant enhancement of pseudovirus infectivity was observed in mock-immunized serum 
when used at high concentrations (less than 1:100 dilution; shows up as negative 
neutralization).  The reason for this phenomenon is not yet known.  Antibody competition 
analyses also indicated that antibodies that could compete with bnAbs VRC01 and PGT121 
in binding gp120 were also maintained (Fig. 1D), albeit at a slightly lower level compared to 
the level observed after the fifth immunization [43].  All together, these results indicated that 
despite slight reductions in neutralizing activity and antibody levels that compete with 
bnAbs, the overall quality of antibody responses remained largely unchanged despite a 
prolonged resting period.  Based on these results, we decided to further characterize antibody 
responses by generating mAbs.  
  
Generation of hybridomas and epitope mapping analyses by ELISA 
To generate hybridomas, the rabbit was injected intravenously with 1 mg of soluble 
gp120 in PBS without adjuvants at week 76.  Four days later, splenocytes were harvested for 
generating hybridomas.  From ten 96-well plates used for the fusion, 548 hybridomas were 
generated.  Hybridoma supernatants were collected and screened for gp120 binding by 
ELISA.  In total, 95 clones were gp120-specific (17.3% cloning efficiency) although two 
were lost during propagation.   
With a long-term goal of establishing a vaccine-induced “antibodyome” database for 
gp120, we initiated an effort to define the epitopes recognized by the mAbs by doing ELISA 
with culture supernatant.  A number of envelope-derived protein constructs as well as 
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peptides were used, including gp120-OD (MCON6 gp120 outer domain we reported 
recently; [42]), BG505 SOSIP gp140 (soluble, stable trimeric envelope; [49,50]), eOD-GT6 
(engineered outer domain that can bind germline BCR of VRC01; [51]), as well as V3 and 
V5 peptides, both of which were highly immunogenic [43].  Results from these ELISA are 
summarized in Fig. 2.  The mAbs could be divided into four main groups:  (1) bind gp120 
only, (2) bind gp120 and SOSIP gp140, but not gp120-OD, (3) bind gp120 and gp120-OD, 
but not SOSIP gp140, and (4) bind all three proteins.  Additional hybridomas in group 5, 
which have not been tested for reactivity to gp140, would belong to either group 1 or group 
2.  They were not tested further due to shortage of samples and because they were not of 
significant interest as they tested negative to all other screens.  Hybridomas in group 6 
exhibited low reactivity to gp120.  Most of them reacted only with gp120 and would belong 
to group 1.  However, due to their low antibody levels, some caution is warranted about their 
antigen-binding profile.   
Most likely, the mAbs belonging to group 1 would bind to epitopes in the inner 
domain of gp120 that would be absent in the gp120-OD and inaccessible on SOSIP gp140 
due to its trimeric state.  The mAbs belonging to group 2 also likely bind to the inner domain 
of gp120, but accessible on SOSIP gp140 unlike those belonging to group 1.  Based on 
overlapping peptide ELISA analyses, the rabbit #2 mounted strong antibody responses 
against several peptides within the inner domain, including those in regions C1 (peptides 
8991, 8992 and 9003), C2 (peptides 9033, 9035 and 9036), and C5 (9090, 9094 and 9096).  
All of these peptides are present and should be accessible to antibodies on SOSIP gp140, 
except for peptides 9094 (489VKIEPLGVAPTKAKR503) and 9096 
(497APTKAKRRVVEREKR511) in the C5 region (Fig. 3).  Peptide 9003 
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(118PCVKLTPLCVTLNCT132), which lies just upstream of the V1 loop, is situated at the top 
of the trimeric structure.  Peptides 8991 and 8992 (70ATHACVPTDPNPQEI84 and 
74CVPTDPNPQEIVLEN88, respectively) are on the bottom of the trimer.  Peptides 9033, 
9035 and 9036 (240KNVSTVQCTHGIKPV254, 248THGIKPVVSTQLLLN262 and 
252KPVVSTQLLLNGSLA266, respectively) are situated closer to the outer domain, with the 
latter two peptides encompassing a part of the outer domain (256STQLLLNGSLA266).  To 
confirm our predictions, many of the mAbs in groups 1 and 2 were further probed with the 
indicated peptides.  Surprisingly, 20 out of 40 (50%) mAbs tested were reactive against 
peptide 9096, indicating it is extremely immunogenic on soluble gp120.  Three mAbs in 
group 2 (4-2, 6-10 and 8-24) tested positive to both peptides 8991 and 8992.  Interestingly 
mAb 5-37 in group 1 reacted to both peptides 9035 and 9036.  However, mAb 9-59 in group 
2 tested positive only against peptide 9035, indicating a clear difference in the amino acids 
residues being recognized and/or the angle of approach in epitope binding. 
There were seven mAbs that belonged to group 3, which bound gp120-OD, but not 
SOSIP gp140.  These mAbs might bind epitopes available on monomeric gp120 and gp120-
OD, but inaccessible on the trimeric SOSIP gp140.  Overall, MCON6 and BG505 share 81% 
amino acid sequence identity.  Thus, another possibility is that the amino acid sequences 
between MCON6 and BG505 are different at these epitopes.  One interesting observation is 
that mAb 5-12 was able to bind not only V5 loop peptide (GNNSNKNKTETFRPG), but it 
was the only mAb that could bind eOD-GT6.  Surprisingly, amino acid sequence alignment 
analyses of the region around the V5 loop showed that SOSIP gp140 sequence is actually 
more homologous to MCON6 gp120 than is eOD-GT6 (Fig. 4).  At the present time, it is not 
known why 5-12 mAb binds to MCON6 gp120, gp120-OD and eOD-GT6, but not SOSIP 
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gp140.  Finally, there were ten mAbs in group 4 that could bind gp120, gp120-OD and 
SOSIP gp140.  Seven of these mAbs bound the V3 loop (1-35, 1-36, 2-37, 8-34-1, 9-13, 
10A3 and 10A37) and two mAbs bound the V5 loop peptide (2-5-1 and 9-6).  None of the 
other mAbs tested positive against the V3 loop.  Overall, there were only 17 mAbs that were 
directed against the outer domain of gp120 (about 18%).  Thus, mAbs against the V3 loop 
accounted for about 7.5% of all mAbs recovered and about 42% of all mAbs directed against 
the outer domain. 
 
Neutralizing activity and competitive binding to or near the neutralizing epitopes   
Since the serum from the rabbit showed significant competition against VRC01 and 
PGT121 (Fig. 1D), we screened all hybridomas for competing activities against these bnAbs.  
Unfortunately, we did not detect any hybridomas that could compete against VRC01 for 
gp120 binding, suggesting that such antibodies might be rare.  Given that only a small 
fraction of splenocytes likely have yielded hybridomas, it is probable that B cells expressing 
VRC01 competing antibodies were not incorporated into our panel.  While screening for 
mAbs that could compete against PGT121, we found seven hybridomas that possessed low, 
but definite activity (Fig. 5A).  Interestingly, all of the competing hybridomas were reactive 
against the V3 loop peptide (Fig. 2) suggesting that serum competition observed against 
PGT121 might be due to the strong anti-V3 antibody response.  Another mAb, 9-6 from 
group 4 that did not bind V3 but bound the V5 loop, exhibited no competing activity.  
Finally, we screened all the hybridomas for neutralizing activity against tier 1 pseudoviruses 
SF162.LC and MW965.26.  Culture supernatants from two V3 peptide positive hybridomas, 
10A3 and 10A37, showed strong neutralizing activity (data not shown; see below).  
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Detailed characterization of anti-V3 loop mAbs. 
Since all anti-V3 loop mAbs could compete against PGT121 and two of them 
exhibited neutralizing activity, all of them were further characterized.  First, fine epitope 
mapping analysis was done using overlapping 15-mer linear peptides that span the entire 
length of the V3 loop (Fig. 6).  The ELISA result demonstrated that peptide 9048 
(NNNTRKSIRIGPGQA) was the most immunoreactive segment in the V3 loop, as five 
mAbs could interact with this peptide. This is consistent with an observation that N-terminal 
half of the V3 loop is more immunogenic than the C-terminal half [42,43].   mAbs 1-36 and 
8-34-1 recognized only peptide 9048.  Another pair, 2-37 and 9-13, bound to peptides 9047 
(CTRPNNNTRKSIRIG) and 9048.  Hybridoma 1-35 was only weakly positive to peptide 
9050 (RIGPGQAFYATGDII).  The two hybridomas that were identified as having 
neutralizing activity, 10A3 and 10A37, exhibited totally different peptide recognition 
patterns.  10A3 reacted most strongly against peptide 9049 (RKSIRIGPGQAFYAT), but 
also recognized peptides 9047 and 9048.  The peptide 9049 has the tip of the V3 crown 
(GPGQ) almost exactly at the center.  This would suggest that mAb 10A3 has the profile of 
many other anti-V3 loop neutralizing mAbs, such as 447-52D [52], and HGN194 [53].  In 
contrast to 10A3, 10A37 strongly reacted against peptide 9050 and moderately to peptide 
9051 (GQAFYATGDIIGDIR).  Out of the seven mAbs, 10A37 was the only one that 
recognized peptide 9051, indicating that recognition of C-terminal half of the V3 loop is 
indeed rare.  In this regard, 10A37 is a novel V3 loop mAb.   
To further characterize V3 mAbs at the molecular level, antibody genes were RT-
PCR amplified from hybridomas, sequenced and analyzed using IMGT/V-QUEST database 
[48].  First, many of the mAbs utilized the same germline V genes (Fig. 7).  Four of the 
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mAbs (10A37, 1-36, 2-37 and 10A3), including the two that exhibited neutralizing activity 
used V1S45*01 VH gene.  mAbs 8-34-1 and 9-13 were derived from V1S40*01.  There were 
two pairs of mAbs that used the same Vκ gene (V1S36*01 for 10A37 and 1-35, and 
V1S56*01 for 1-36 and 8-34-1).  One interesting observation is that the light chain of mAbs 
10A37 and 1-35, both of which bound peptide 9050, were nearly identical.  Their LCDR 
sequences differed by a single amino acid difference in LCDR3.  In contrast, HCDR 
sequences, which were derived from different germlines, were only about 53-56% identical, 
which may explain why 1-35 bound peptide 9050 only weakly and failed to exhibit 
neutralizing activity.  Additional structure-function analyses of these mAbs would provide 
critical information that distinguishes their functional properties.        
Similar to 10A37 and 1-35, mAbs 1-36 and 8-34-1, both of which only bound peptide 
9048, were derived from the same V1S56*01 Vκ gene.  Amino acid identities for LCDR1, -2 
and -3 were 63%, 100% and 93%, respectively.  Even though their VH genes were derived 
from different germlines, their HCDR1 and HCDR3 sequences were quite similar (78% and 
63%, respectively), suggesting a possible convergent evolution.  Conversely, there were 
some signs of divergent evolution as well.  For example, mAbs 10A3 and 2-37, both of 
which bound peptides 9047 and 9048, originated from the same V1S45*01 VH germline, but 
their HCDR1, -2 and -3 sequences were markedly different (only 56%, 33% and 20% 
identity, respectively).  These differences might have enabled 10A3 to bind peptide 9049 
strongly and exhibit neutralizing activity.  Similarly, mAbs 8-34-1 and 9-13, both of which 
were derived from the same V1S40*01 VH germline also exhibited low homology (only 
33%, 22% and 50% identity for HCDR1, -2 and -3, respectively).  However, their LCDR 
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exhibited strong similarity despite the fact that they evolved from different germlines, which 
might have allowed both mAbs to bind peptide 9048.      
    
Characterization of recombinant neutralizing mAbs 
To further characterize the neutralizing activity, recombinant mAbs 10A3 and 10A37 
were cloned, expressed and purified.  Their potency and breadth were assessed using a 
standard TZM-bl neutralization assay against a large panel of tier 1 and 2 pseudovirus from 
different clades (Fig. 8).  Recombinant mAb 10A3 neutralized several Clade B and Clade C 
tier 1A and 1B isolates, as well as one tier 2 virus Clade C virus (TV1.21).  Neutralizing 
potency and breadth of mAb 10A37 was more impressive than 10A3, being able to neutralize 
several additional viruses.  In particular, 10A37 exhibited potent neutralizing activity against 
Clade AE virus TH023.6, which was shown to be highly susceptible to the immune sera 
shown in previous report [42].  In addition, 10A37 was able to neutralize tier 2 Clade C virus 
25710-2.43, which is one of the twelve virus isolates that belong to the a new “global panel 
of reference strains” [54].  Unfortunately, 10A37 did not neutralize any of the other eleven 
viruses from the “global panel” (i.e. IC50 >25 µg/ml, data not shown).  10A37 and 10A3, 
combined, were able to neutralize 11 of 15 tier 1A and 1B viruses tested (73%) and only 3/18 
tier 2 viruses (17%).  However, they were insufficient to recapitulate full neutralizing activity 
of antibodies present in the immune serum, which was able to neutralize MN.3 [42].  
In Fig. 5A, we showed that all of the anti-V3 loop mAbs exhibited ability to compete 
with PGT121 for binding gp120.  To confirm that anti-V3 loop antibodies are indeed able to 
compete with PGT121, we used recombinant 10A37.  As shown in Fig. 5B, 10A37 was able 
to efficient compete with PGT121 for binding gp120.  These results suggest that PGT121-
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competing activity we observed in immune sera could actually be due to anti-V3 antibodies, 
rather than true PGT121-like antibodies that bind V3 and a glycan immediately adjacent to 
the C-terminus of V3.    
     Discussion 
 
The field of HIV-1 vaccine development has been aided immensely by the recent 
discovery of new bnAbs [11].  Furthermore, deep sequencing analyses have highlighted the 
complex evolution that the immunoglobulin germline must undergo to generate these rare 
antibodies [55,56].  Additional antibody structural studies, especially when performed in 
complex with HIV-1 envelope glycoproteins, have provided valuable insights for generating 
rationally designed immunogens [49-51].  However, translating the information generated 
from these studies into designing immunogens that can elicit similar bnAbs has been 
difficult.  A critical fact that needs to be kept in mind is that HIV-1 infected individuals 
provide an environment where the virus and the immune system responses co-evolve.  This 
dynamic environment generated by chronic virus infection is difficult to replicate using any 
vaccination regimen.  Hence, while characterization of antibody responses in virus-infected 
individuals is valuable, immunization studies in animal models remain a vital means to 
evaluate realistic vaccine strategies against HIV-1.   
Of all HIV-1 Env immunization studies conducted in animal models, only a limited 
number of studies have attempted to further characterize antibody responses at a clonal level.  
Generating mAbs is a labor intensive and time-consuming process.  However, they can 
significantly aid in understanding the immune response as demonstrated in this study.  First, 
mAbs permit precise mapping of B cell epitopes, which would not be possible using 
polyclonal antisera.  This would provide necessary information to establish a comprehensive 
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map of vaccine-induced antibodyome against HIV-1 envelope glycoprotein, which we 
believe will be critical for developing a vaccine that can induce bnAbs against the virus.  In 
this study, as an initial attempt to define epitopes recognized by what we believe is the 
largest panel of anti-gp120 rabbit mAbs generated to date, we examined antibody reactivity 
against different protein constructs and some of the immunogenic peptides identified from 
overlapping peptide ELISA [43].  Characterization of epitope targets would greatly aid our 
understanding of immune responses against HIV-1.  This report focused primarily on V3 
loop-specific mAbs since two of them exhibited potent neutralizing activity against tier 1 
viruses with marked breadth.  
The V3 loop has been known as the principal neutralizing determinant for over two 
decades [57,58].  Despite the fact that nAbs targeting this epitope exhibit only a limited 
breadth and largely against tier 1 viruses, they are the only ones that could be induced 
consistently in both animals and humans in a vaccine setting.  It should be noted, however, 
that not all anti-V3 loop neutralizing mAbs exhibit equal potency or breadth; while some 
only neutralize autologous vaccine strains, others do exhibit marked breadth.  Most of the 
broadly neutralizing V3 loop mAbs characterized to date have been derived from virus-
infected human patients, including 447-52D that was reported over 20 years ago [52].  
Recently, Hioe et al. [58] tested the breadth and potency of seven human anti-V3 loop 
antibodies.  Their study showed that 56/98 (57%) psuedoviruses tested (both tier 1 and 2 
isolates from Clades A, AG, B, C and D) could be neutralized by one or more mAbs (using 
Area Under Curve-methodology).  More importantly, 9/24 (37.5%) tier 2 viruses could be 
neutralized by one or more mAbs.  In another study, Corti et al. [53] characterized an anti-V3 
mAb HGN194 in direct comparison to 447-52D.  While 447-52D could neutralize only 88% 
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of the tier 1 and 4% of the tier 2 viruses tested, HGN194 was able to neutralize all tier 1 and 
11% of the tier 2 viruses, suggesting superior breadth.                  
In contrast to mAbs generated from virus-infected humans, there are far fewer mAbs 
generated from animals immunized with HIV-1 antigens, especially those that exhibit 
neutralizing activity.  Recently, however, Chen et al. reported the isolation of twelve mAbs 
from a rabbit immunized with a DNA prime-protein boost JR-FL gp120 vaccine regimen 
[39].  One of the antibodies recovered, R56, targeted the V3 loop and neutralized multiple 
tier 1 viruses belonging to Clades B, C, AE and AG as well as two tier 2 viruses in standard 
TZM-bl assays.  It is not easy to compare neutralization potency or breadth of different mAbs 
characterized in different laboratories because not all of the same viruses are tested and the 
assays are not performed with identical virus stocks.  Having said that, the potency of 10A37 
seemed to be greater than those of R56.  For example, 10A37 neutralized five viruses that 
R56 could not, including MS208.A1 (Clade A), 6535.3 (Clade B), ZM109F.PB4, 00836-2.5 
and 25710-2.43 (Clade C).  The neutralization potency (IC50) of 10A37 was also significantly 
greater than R56 for multiple viruses:  TH023.6 (<0.03 vs. 18.57 µg/ml)), SF162.LS (<0.03 
vs. 0.1), Bal.26 (0.15 vs. 2.07), Bx08.16 (0.61 vs. 3.18), SS1196.1 (2.97 vs. 7.18).  The only 
virus R56 neutralized, but could not by 10A37 was TV1.21 (Clade C).  However, 10A3 
could neutralize TV1.21 with greater potency than R56 (5.1 vs. 25.63 µg/ml).  Surprisingly, 
none of the three rabbit mAbs could neutralize MN.3, which is generally considered to be a 
highly sensitive tier 1 isolate.  While there is a known structural basis for the failure of R56 
to neutralize MN.3 [59], the reason for the lack of neutralization by 10A3 and 10A37 
remains to be determined.  Interestingly, neither 10A3 nor 10A37 neutralized 
BG505ΔCT/T332N (data not shown), despite the fact that these two mAbs strongly reacted 
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to SOSIP gp140 by ELISA (Fig. 2).  We speculate that this is possibly due to the V3 loop of 
SOSIP gp140 being exposed during normal coating of the protein onto ELISA plates.  In this 
regard, a gentler sandwich ELISA protocol might be more appropriate. 
 One of the advantages of mAbs is that they allow functional separation of antibodies 
with different properties.  As such, one of our objectives was to isolate mAbs that could 
compete against bnAbs VRC01 or PGT121 in binding gp120.  Unfortunately, we were 
unable to identify any VRC01-competing mAbs.  On the other hand, we identified seven 
mAbs that could compete with PGT121 and these turned out to be specific for the V3 loop.  
This result indicates that PGT121-competing activity we detected in immune sera [43] is 
likely due to a high level of antibodies against the V3 loop.  This finding highlights a 
possibility that induction of high titers of V3 loop antibodies might prevent eliciting more 
effective PGT121-like antibodies.  As such, it might be prudent to minimize immunogenicity 
of the V3 loop in future immunogen design.     
 One other important benefit of working with mAbs is the ability to evaluate antibody 
repertoire and function at the molecular level.  This is particularly useful when evaluating 
multiple mAbs that target nearby epitopes at a given region (e.g. V3 loop), yet exhibit 
different functional phenotypes (e.g. neutralizing vs. non-neutralizing).  Neutralizing mAb 
10A37 and non-neutralizing mAb 1-35 are good examples.  These mAbs target the same 
epitope (i.e. RIGPGQAFYATGDII), albeit with different affinity.  Although their light 
chains originated from the same germline and are virtually identical in sequence, their heavy 
chain sequences are quite divergent, which would indicate that the differences in their heavy 
chains likely account for the phenotypic difference.  One could speculate that the heavy chain 
germline used by 1-35 (IGHV1S7*01) might be poorly primed for efficient affinity 
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maturation.  In contrast, the 10A37 germline might have been better able to undergo affinity 
maturation, as evidenced in part by the overall preference for IGHV1S45*01 and the closely 
related IGHV1S40*01 in V3-binding antibodies.  It should be emphasized that mAbs we 
generated likely represent only a small subset of all antibodies that could bind any given 
epitope.  As such, they provide only a snapshot of a long evolutionary pathway.  Sequence 
profiling of all the expressed antibodies in the immunized animal using NGS would provide 
the means by which to examine differences in the maturation pathways of neutralizing versus 
non-neutralizing antibodies without the limitations imposed by hybridoma production.  
Assuming that all B cells have an equal chance of being fused into hybridomas and 
that specificity of antibodies have no affect on survivability of the hybridomas, the frequency 
of hybridomas targeting a given epitope should represent the relative immunogenicity of the 
epitope.  In this regard, the single most frequent epitope recognized by the mAbs is the 9096 
peptide (20 of 93 mAbs), which we had previously identified as the single most 
immunogenic peptide based on ELISA with antisera.  The 9096 peptides lies at the very C-
terminus of gp120.  The next most immunogenic epitope is the V3 loop.  Considering that 
antibodies that bind these epitopes are either non-neutralizing or neutralizing with limited 
breadth, a better immunogen or a vaccine strategy would be needed to improve focusing 
immune responses towards epitopes targeted by bnAbs.  Although we have not succeeded in 
inducing bnAbs in this study using MCON6 gp120, the methodologies we have established 
and the reagents we have generated should facilitate evaluation of antibody responses against 
other immunogens or vaccine strategies in the future.   
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Conclusions 
 
In this study, antibody responses against MCON6 gp120 in a rabbit were further 
characterized at a clonal level using a large panel of monoclonal antibodies (mAbs) 
generated from the immunized animal.  Epitopes were defined using a set of different 
envelope protein constructs as well as linear peptides.  The most immunogenic epitope was at 
the C-terminal end of the protein, followed by the V3 loop.  Two new neutralizing antibodies 
(nAbs) against the V3 loop were isolated (10A3 and 10A37).  While 10A3 was similar to 
many previously isolated neutralizing mAbs recognizing the N-terminal half of the V3 loop 
including the crown at the tip, 10A37 was atypical with its epitope positioned more towards 
the C-terminal half of the loop.  10A37 exhibited potent neutralizing activity with substantial 
breadth against multiple clades of HIV-1 that exhibit a tier 1A and tier 1B neutralization 
phenotype.  To our knowledge, it is the most potent and broadly neutralizing anti-V3 loop 
mAb isolated from a vaccinated animal or human to date.  Further characterization of its 
structure as well as the epitope it binds could provide important insights into the 
neutralization mechanism. 
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                                                               Figures 
 
 
Figure 1. Characterization of antibodies induced after the 6th immunization. (A) 
Timeline of immunization and sample collection.  (B) Comparison of antigen-specific 
antibody titers after the 5th, before 6th, and after 6th immunization.  A serum sample 
from an age matched, mock-immunized animal, indicated as “PBS”, was used as a 
negative control.  A450 represents absorbance value at 450 nm.  The same legend at 
the bottom is used for all of the panels.  (C) Neutralizing activity against MN.3, 
MW965.26 and SF162.LS.  (D) The serum sample after the 6th immunization was 
tested for competition against VRC01 and PGT121.   
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Figure 2.  Epitope mapping analyses of hybridomas generated.  Hybridomas were 
evaluated for reactivity against gp120, gp120-OD, BG505 SOSIP gp140, as well as 
variable loop peptides V3 and V5, and peptides from the inner domain (ID-P).  
Hybridomas are arranged in groups based on their reactivity to three proteins as 
discussed in the text. 
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Figure 3.  Locations of immunogenic peptides in the inner domain.  The crystal 
structure of trimeric BG505 SOSIP gp140 (pdb: 4NCO) was used to illustrate 
location of the immunogenic peptides in the inner domain.  Only the gp120 portion is 
shown for clarity.  The outer domain is shown in lime and the inner domain is shown 
in three shades of gray.  A part of peptide 9094 and 9096 from the C5 region 
(indicated in a lighter magenta shade) are not shown in the crystal structure.  The 
arrow points to the position of the five amino acids (VKIEP) on peptide 9094.   
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Figure 4.  Sequence alignment of a region around the V5 loop.  Sequences for the 
three antigens used for ELISA are shown (MCON6 gp120, BG505 SOSIP gp140 and 
eOD-GT6).  The V5 loop peptide used for ELISA is boxed in.  Identical amino acid 
residues are indicated in red.  The residues that make contact with bnAb VRC01 or 
CD4 are indicated as red or cyan circles. 
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Figure 5.  Antibody competition against PGT121.  (A) Culture supernatants of 
hybridomas specific against the V3 loop were evaluated for competing activity 
against PGT121 for binding gp120.  (B) Recombinant mAb 10A37 was used for the 
competition assay.  Anti-gp41, recombinant mAb 2C2 was used as a negative control. 
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Figure 6.  Epitope mapping analyses of anti-V3 loop mAbs.  The V3 loop-positive 
antibodies were tested for binding to overlapping 15-mer peptides spanning the entire 
loop by ELISA.  The sequences of the peptides are shown at the bottom.   
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Figure 7.  Comparison of CDR regions of the anti-V3 loop mAbs.  The heavy and 
light chains of the seven V3 loop-positive mAbs were aligned for analysis.  
Comparison was done based on peptide reactivity shown in Fig. 6.  Percentages 
indicate % amino acid identity between the two CDR being compared. 
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Figure 8.  Neutralizing activity of anti-V3 loop mAbs 10A3 and 10A37.  V3 positive 
mAbs 10A37 and 10A3 were tested for neutralization against pseudoviruses 
belonging to different clades and tiers of HIV-1 and their IC50 values were reported.  
These mAbs were compared to a combination of two mAbs (CH01 and VRC-CH31) 
that are known to show broad cross-clade neutralization. 
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